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ABSTRACT 
Current therapies for diabetes mellitus are insufficient to prevent the 
devastating complications associated with this disease. A novel approach for the 
treatment of diabetes is the restoration of an insulin-producing ~-cell mass through the 
stimulation of endogenous progenitor cells. Thus, the aim of this thesis was to 
determine if pharmacological initiation of islet neogenesis and subsequent ~-cell mass 
expansion will lead to the reversai of hyperglycaemia in a response that is under 
homeostatic regulation and has efficacy in humans. 
A pentadecapeptide fragment of Islet Neogenesis Associated Protein 
(INGAp104-108), was administered to normoglycaemic hamsters and was found to result 
in an expanded ~-cell mass as measured by immunohistochemical morphometric 
analysis. This expansion was shown to occur through the transformation of duct- and 
acinar-associated progenitors. In order to determine if this therapeutic approach 
would be effective in mammals other th an hamsters, INGAp104-118 was administered to 
normoglycaemic mice, dogs and monkeys, hyperglycaemic mice, and to human 
pancreatic tissue cultures. 
INGAp104-118 administration led to a dose-dependent increase of ~-cell mass in 
mice, with similar trends observed in dogs. Similarly, administration of INGAp104-118 to 
normoglycaemic monkeys for 90 days resulted in profound areas of islet neogenesis. 
Administration of INGAp104-118 to diabetic mice resulted in restoration of euglycaemia 
and a dramatic increase in ~-cell mass_ Furthermore, INGAp104-118 administration to 
cultured human acinar tissue, led to the formation of insulin-producing islet-like 
structures. These results suggest that INGAp104-118 therapy has the ability to reverse a 
diabetic state and could be effective in humans. However, it was necessary to 
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determine whether the continuai stimulation of islet neogenesis through INGApl04.118 
administration is a safe therapeutic approach. 
The f3-cell mass dynamics of euglycaemic mice administered INGApl04.118 at 
various doses for 31 or 90 days were determined. f3-cell mass was greatly increased 
at 31 days of therapy, though by 90 days of therapy there was no difference in total 13-
cell mass between ail treatment groups. However, there were marked instances of 
islet neogenesis in mice treated with INGApl04-118 for 90 days. This elevation in islet 
neogenesis was tempered by decreased f3-cell replication and increased f3-cell 
apoptosis, resulting in no ove rail difference in total f3-cell mass. These results 
suggest that inherent homeostatic regulation persisted to maintain a net f3-cell mass 
that matched the physiological need, even in the setting of continuai induction of islet 
neogenesis. 
INGApl04.118 therapy has been shown to expand the insulin-producing f3-cell 
mass in a safe homeostatic manner and reverse diabetic hyperglycaemia. These 
findings suggest that a nover pharmacological agent for the successful stimulation of 
f3-cell mass expansion is within reach, enabling new therapeutic modalities for the 
treatment of diabetes. 
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RÉSUMÉ 
Les thérapies actuelles ciblant le diabète mellitus sont insuffisantes pour 
éviter les complications associées à cette maladie. Une nouvelle approche de 
traitement du diabète serait de stimuler les cellules progénitrices endogènes des 
cellules b qui produisent l'insuline. Ainsi, le but de cette thèse a été de déterminer 
si l'initiation par un agent pharmacologique de la néogénèse des îlots de 
Langerhans, et l'expansion des cellules 13 qui en découle, peut mener à la 
suppression de l'hyperglycémie par un effet sous contrôle homéostatique et 
efficace chez l'humain. 
Un fragment d'INGAP (Protéine Associée à la Néogénèse des lIots) de 15 
acides aminés: (INGAp104.118) a été administré à des hamsters normoglycémiques 
et a eu pour effet l'augmentation de la masse de cellules 13. Il a été montré que 
cette expansion se produit par transformation des progéniteurs associés aux 
canaux et acini. Dans le but de déterminer si l'approche thérapeutique serait 
efficace chez d'autres mammifères que les hamsters, INGAp104.118 a été 
administré à des souris, des chiens et des singes normoglycémiques, à des souris 
hyperglycémiques ainsi qu'à des cultures de tissus pancréatiques humains. 
L'administration d'INGAp104-118 augmente de façon dose-dépendante la 
masse de cellule 13 chez les souris. La même tendance a également été observée 
chez les chiens. De même, l'administration pendant 90 jours d'INGAp104-118 aux 
singes normoglycémiques stimule la néogénèse des îlots. Chez les souris 
diabétiques, l'administration d'INGAp104-118 permet de restaurer l'euglycémie et 
augmente de façon importante la masse de cellules 13. Il a également été observé 
que les cultures de tissus acinaires humains, traitées avec INGAp104-118 forment 
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des strucutures similaires aux îlots et qui produisent de l'insuline. Ces résultats 
suggèrent que l'administration d'INGApl04-118 a la capacité de supprimer un état 
diabétique et pourrait être efficace chez l'homme. Cependant, il a été nécessaire 
de déterminer si la stimulation en continue de la néogénèse des îlots par 
INGApl04-118 est une approche thérapeutique sans danger. 
La dynamique de la masse de cellules j3 a été déterminée chez des souris 
euglycémiques auxquelles INGApl04-118 a été administré à des doses diverses 
pendant 31 ou 90 jours. La masse de cellules j3 est considérablement augmentée 
à 31 jours de traitement. Cependant, aucune différence concernant la masse 
globale de cellules j3 ne subsiste entre les différents groupes après 90 jours de 
traitement. Mais, chez les souris traitées avec INGApl04-118, des îlots néoformés 
ont pu être observés. Cette augmentation de formation de nouveaux îlots est 
atténuée par une diminution de la réplication des cellules j3 et par une 
augmentation de l'apoptose de ces cellules. Ceci explique pourquoi aucune 
différence dans la masse globale n'a pu etre observée. Ces résultats suggèrent 
qu'un contrôle homéostatique persiste pour maintenir une masse de cellules j3 
correspondant aux besoins physiologiques, et ceci malgré la stimulation en 
continue de la néogénèse des îlots. 
Ainsi, il a été démontré que l'administration d'INGApl04-118 permet 
d'augmenter la masse de cellules j3 sans danger et de supprimer l'hyperglycémie 
diabétique. Ces résultats suggèrent que la réalisation d'un nouvel agent 
pharmacologique stimulant la croissance de la masse de cellules j3 est sur le point 
d'être atteint, permettant ainsi de nouvelles possibilités de traitement du diabète. 
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PREFACE 
The aim of this thesis was to determine the potential of pharmacological 
induction of j3-cell mass expansion to lead to restoration of euglycaemia in 
individuals with diabetes mellitus. This thesis is composed of 6 chapters including 
the first in which a general introduction to diabetes, current therapies, and 
potential new therapeutic avenues are discussed. Chapter 2 examines the 
potential of INGAP peptide (INGAp104.118) to lead to j3-cell mass expansion in both 
normoglycaemic hamsters and mice. As weil, the ability of INGAp104·118 to induce 
j3-cell neogenesis and reverse hyperglycaemia in a mouse model of type 1 
diabetes is assessed. This work is published in Anna/s of Surgery (240: 875-884, 
2004). In Chapter 3, evidence for the homeostatic regulation of induced j3-cell 
mass expansion is analysed resulting in the determination that unbridled cellular 
expansion does not occur in the setting of continuai stimulation of islet 
neogenesis. This work is published in Diabetologia (49: 2910-2919, 2006). 
Chapter 4 explores the potential of INGAp104.118 therapy to expand human j3-cell 
mass in a novel model of cellular differentiation. This work is published in 
Pancreas (in press). Chapter 5 examines the current state of therapy for type 1 
diabetes as weil as future avenues for the successful amelioration of the disease. 
This work has been published in International Journal of Biochemistry and Ce" 
Biology (38: 498-503, 2006). Chapter 6 contains the discussion of results borne 
from this thesis and how the findings herein expand our understanding of potential 
therapies for diabetes mellitus. 
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INTRODUCTION 
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1.1 DIABETES MELLITUS 
Diabetes mellitus is a metabolic disease in which an insufficient secretion 
of the pancreatic hormone insulin leads to chronically elevated blood glucose 
levels (hyperglycaemia) [1]. Diabetes afflicts approximately 3% of the global 
population with the disease being most prominent in industrialized countries 
where the national averages reach approximately 8% [2, 3]. Chronic 
hyperglycaemia associated with diabetes results in damage to many organ 
systems including the kidneys, eyes, heart, blood vessels and nervous system [4]. 
Diabetes is the single most common cause for end-stage renal disease with 20 to 
30% of patients with diabetes developing evidence of nephropathy [5]. Similarly, 
more than 60% of individuals with diabetes develop retinopathy during their 
lifetime [5]. The World Health Organization has recently described diabetes as 
one of the most devastating global threats to human health, attributing an 
estimated 3 million deaths per year to this disease [6]. 
There are two major types of diabetes mellitus: type 1 (formerly referred to 
as juvenile onset, and accounting for approximately 10% of ail cases of diabetes 
mellitus) and type 2 (adult onset) diabetes. The aetiology of type 1 diabetes has 
yet to be fully understood, though it appears to involve coordinated interactions of 
both genetic predisposition and environmental stimuli. Type 1 diabetes results 
from the autoimmune destruction of the insulin-producing pancreatic f3-cells that 
are located in the islets of Langerhans [7, 8J. Clinicallyobservable type 1 diabetes 
typically occurs when the normal f3-cell mass has decreased by approximately 
80% [7]. Virtually ail endogenous insulin production is eliminated in individuals 
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with type 1 diabetes, and as such, these patients must administer exogenous 
insulin to regulate blood glucose levels. 
Type 2 diabetes is characterized by both insufficient insu lin secretion and 
resistance to the action of insulin [1]. Insufficient insulin secretion in type 2 
diabetes may be due to reduced ~-cell mass and/or impaired J3-cell function [7, 9-
11]. Overt type 2 diabetes is associated with a 50 to 60% lower ~-cell mass as 
compared to weight matched non-diabetic control subjects [7, 9, 12]. 
Inappropriate diet and exercise levels have been associated with type 2 diabetes 
as excessive adipogenesis and lack of sufficient exercise can result in increased 
insulin resistance [7]. Moreover, elevated blood lipid and glucose levels are 
believed to stimulate J3-cell death through a synergistic mechanism [13]. 
Decreased peripheral insulin sensitivity leads to increased ~-cell demand. Under 
stress, insulin processing in J3-cells is disrupted leading to increased release of the 
less efficacious pro-insulin, in place of fully-processed insulin [14]. As weil, 
increased stimulation of insulin release from the pancreatic J3-cells can result in 
elevated release of islet amyloid polypeptide (IAPP) [12, 15]. IAPP has 
fibrilogenic properties that can lead to plaque formation and result in ~-cell death. 
IAPP plaques have been associated with up to 90% of ail cases of type 2 diabetes 
[16,17]. 
Both type 1 and type 2 diabetes results from an insufficient level of 
circulating insulin to meet the body's needs. Even though their aetiologies may be 
different, the respective reduction in ~-cell mass and the lack of an appropriate 
regenerative response can be seen as the ultimate foundation of this disease. 
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1.2 ADULT PANCREATIC ANATOMY 
The adult human pancreas is a multilobular organ situated in the 
retroperitoneal space. It can be divided roughly into three portions; namely the 
head, body and tai!. The head of the pancreas connects to the proximal 
duodenum via the am pula of Vater, whereas the tai! is juxtaposed to the spleen. 
The pancreas can vary in mass between 50 and 170 grams depending on an 
individual's size. The organ is comprised of three major cell phenotypes: the 
endocrine, acinar, and duct cells (Figure 1.1). 
1.2. 1 The Exocrine Tissue 
The acinar and ductal components comprise the exocrine portion of the 
pancreas and account for more than 95% of the total organ mass. Pancreatic 
acini, which accounts for approximately 80% of the parenchymal tissue, produce 
digestive zymogens that are secreted into the ductal network, and subsequently 
transported to the digestive tract [18). Centroacinar cells connect the acinar cells 
to the ductal network. These cells produce large amounts of bicarbonate and 
other non-digestive components of the pancreatic juice [19, 20]. The remaining 
15 to 20% of the exocrine pancreas consists of the ductal network. Pancreatic 
ducts vary in size from small, intercalated ducts, to the largest main pancreatic 
duct [21, 22]. Similar to centroacinar cells, duct cells produce bicarbonate and 
other non-digestive elements of the pancreatic juice. 
The ductal components of the exocrine pancreas have long been thought 
to harbour the regenerative potential of the organ. In support of this notion, Pour 
et al. have indicated that centroacinar cells can develop into both endocrine and 
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Figure 1.1: Pancreatic morphology. A photomicrograph of a pancreatic section in 
which there is a pancreatic duct, acinar tissue (blue ce" clusters) and an insulin 
stained islet of Langerhans (brown). (bar = 25 ~m) 
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exocrine tissues during pancreatic development [23). Furthermore, centroacinar 
cells have elevated expression of the stem cell regulatory factor notch, which is a 
key component in maintaining progenitor ce Ils in an undifferentiated state during 
pancreatic ontogeny [19, 20]. As such, these cells are thought to contain 
regenerative capabilities and may be implicated in the development of pancreatic 
adenocarcinoma [20, 23-25]. The role of the ductal epithelium in pancreatic 
regeneration will be described in more detail later. 
1.2.2 The Endocrine Tissue 
Endocrine cells, which comprise only 1-3% of the pancreas, are generally 
organized into clusters referred to as islets of Langerhans [26]. An average islet 
has a diameter of approximately 150 f.tm and consists of approximately 4000 cells. 
Four distinct endocrine cells may be contained within an islet including: insulin-
producing j3-cells (approximately 80% of ail endocrine cells), glucagon-producing 
a-cells (approximately 10%), somatostatin-producing ô-cells (approximately 5%) 
and pancreatic polypeptide-producing PP-cells (approximately 5%) (Figure 1.2) 
[26,27]. 
Islets are extremely weil vascularized, receiving approximately 20% of the 
total organ blood flow to facilitate their endocrine function [26, 28]. Arterial blood 
initially flows to the j3-cell core and is then directed to the a- and ô-cells, which 
constitutes the basis for coordinated hormonal release [29-32]. In addition to 
having intricate circulatory pathways, islets are also heavily innervated. 
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Figure 1.2: Pancreatic islet. A representative islet of Langerhans indicating the 
organized cellular structure of a core of insulin-producing ~-cells surrounded by a 
mantle of glucagon-producing a-cells, somatostatin-producing ô-cells and 
pancreatic polypeptide-producing PP-cells. 
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The cellular distribution of pancreatic islets is highly organized in lower 
mammals with a defined central core of (3-cells surrounded by a mantle of the 
other three endocrine cell types. This organization is less defined in primates and 
humans [33]. In addition to residing within islets, sorne endocrine cells are found 
as single cells or sm ail clusters of cells distributed throughout the acinar tissue or 
in association with duct structures [34-37]. 
Insulin and glucagon are the principal endocrine hormones involved in 
regulating blood glycaemia. Insulin reduces blood glucose levels by stimulating 
glucose uptake from the blood into target tissues. Insulin binding to its receptor 
initiates a signalling cascade that ultimately leads to the translocation of 
intracellular vesicles, containing glucose transporter-4 (GLUT-4), to the cell 
surface [38]. Glucose then moves down its concentration gradient and into the 
cells via GLUT-4. Once inside the cell, glucose has one of two possible fates. It 
can be metabolized through glycolysis and the citric acid cycle, or it can be stored 
as either glycogen or lipids via glycogen synthase and various lipid synthase 
enzymes, respectively [39]. 
The (3-cell has a remarkably elegant regulatory system that rapidly reacts 
to fluctuating blood glucose levels to maintain appropriate levels of circulating 
insulin. This system is initiated by the introduction of glucose into (3-cells via 
GLUT-2 in rodents and GLUT-1 in humans [40, 41]. Once glucose is inside the (3-
cell, it is metabolized through the citric acid cycle leading to an increased 
intracellular adenosine triphosphate (A TP) concentration. The elevation of 
intracellular ATP causes ATP-sensitive potassium channels to close, resulting in 
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the depolarization of the cell (42). Cellular depolarization opens voltage-sensitive 
calcium channels and the intracellular calcium concentration increases [43, 44). 
Elevation of the intracellular calcium concentration activates the vesicle docking 
proteins, SNAREs, SNAPs and calpains, which leads to the exocytosis of insulin-
laden secretory granules (45). 
The main product of pancreatic a-cells is glucagon (46). Glucagon is 
produced through the processing of pre-pro-glucagon, which can also be cleaved 
to form glicentin, oxyntomodulin, glucagon-like peptide-1 (GLP-1) or GLP-2 [46, 
47). Within pancreatic a-cells essentially ail pre-pro-glucagon is cleaved to form 
glucagon. Glucagon release is promoted by low circulating blood glucose levels 
and is suppressed by insulin and somatostatin (48). The main action of glucagon 
is to elevate blood glucose levels by stimulating the breakdown of glycogen into 
free glucose molecules, as weil as stimulating gluconeogenesis by the liver. 
Somatostatin is the main product of pancreatic ô-ce Ils (49). Similar to its 
inhibitory effects in the nervous and gastrointestinal systems, pancreatic 
somatostatin suppresses both insulin and glucagon release from f3- and a-cells, 
respectively. While gastric tissue secretes large amounts of somatostatin, it is 
thought that the small amount of somatostatin produced and secreted by 
pancreatic ô-cells only affects pancreatic endocrine and exocrine function (49). 
The PP-cells are responsible for producing pancreatic polypeptide. Very 
little is known about the function of pancreatic polypeptide though it has been 
suggested to act as an inhibitor of gastric emptying [50]. 
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1.2.3 The Integrated Organ 
Historically, the pancreas has been described as containing two separate 
organs; the enzyme producing exocrine portion and the metabolic endocrine 
portion [51, 52]. Histological analyses, as weil as in-depth expression assays, 
have indicated that there is a very structured organization of the pancreas with 
numerous interactions between the three main cell types. The pancreatic islets 
are not randomly distributed throughout the organ but are more likely to be near, 
or juxtaposed to, pancreatic ducts [52). Furthermore, there are clear distinctions 
between acini that are in close proximity to islets versus those that are not [53-56]. 
Peri-insular acini, or acini situated near islets, are larger, contain greater numbers 
of zymogen granules, and express higher levels of digestive enzyme mRNA than 
tele-insular acini [55, 57, 58]. The intricate cellular organization of the pancreas 
suggests that rather than existing as two separate organs, the pancreas functions 
as a singular intercalated organ with each cell type interacting together to ensure 
an appropriate balance of exocrine and endocrine function [51, 52]. 
1.3 CURRENT THERAPEUTIC OPTIONS FOR DIABETES MELLITUS 
1.3.1 Discovery of Insulin 
A diagnosis of diabetes mellitus was a virtual death sentence prior to the 
identification and isolation of insulin, credited to Banting, Best, Collip and Macleod 
in 1922 [59]. Banting and Best initially administered their purified insulin to 
pancreatectomized dogs resulting in the amelioration of hyperglycaemia, and 
soon after, recapitulated these results in type 1 diabetics. Of note, Constantin 
Paulescu used a pancreatic extract to reverse hyperglycaemia in dogs in 1916, 
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then reconfirmed this and published the results in 1921 [60]. Unfortunately, he 
was not able to purify this extract sufficiently for human therapy prior to Banting, 
Best, Collip and Macleod [61]. Once insulin was isolated and administered to 
diabetic patients, the immediate results were so overwhelmingly positive that it 
was believed a cure was in hand. 
1.3.2 Insulin Augmentation 
ln addition to insulin administration, conventional therapies for diabetes 
mellitus include diet modification, exercise and medications that either increase 
insu lin release (sulphonylureas) or enhance insulin sensitivity (thiazoladinediones 
and biguanides). However, these therapies are not sufficient to prevent the 
complications associated with diabetes [62, 63]. Two major studies, the Diabetes 
Control and Complications Trial (DCCT) and the United Kingdom Prospective 
Diabetes Study (UKPDS) demonstrated that intensive diabetes management can 
slow the progression of diabetic complications, but not affect overall mortality [62, 
63]. Intensive insu lin therapy pertormed in the DCCT resulted in a 50% reduced 
risk of retinopathy and a 69% decrease risk of neuropathy in individuals with type 
1 diabetes [62]. In the UKPDS intensive treatment led to a 25% risk reduction in 
microvascular endpoints for individuals with type 2 diabetes, although there was 
no significant reduction in diabetes-related mortality [63]. 
While intensive treatment can reduce the risk of developing complications, 
it also increases the frequency of hypoglycemic episodes. In both the DCCT and 
UKPDS, intensive therapies were associated with a 2- to 3-fold increase in the 
frequency of severe hypoglycemic episodes requiring third party assistance [62, 
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63J. A potentially superior alternative to insulin augmentation therapy is the 
restoration of a glucose-sensing, insulin-producing J3-cell mass. 
1.3.2 Surgical Manipulations 
Currently, surgical manipulations are the only successful means for 
increasing J3-cell mass in diabetic individuals [64]. This can be achieved through 
either whole organ pancreas transplantation or isolated islet transplantation. 
Furthermore, a surgical duct ligation therapy performed by de Takats in the late 
1920s and early 1930s, appears to have resulted in at least partial restoration of a 
glucose-sensing insulin-producing J3-cell mass [65-68]. 
1.3.2.1 Pancreatic Ligation 
Shortly after the discovery and isolation of insulin, de Takats was 
performing an experimental surgical procedure on patients with type 1 diabetes. 
His pancreatic ligation procedure resulted in an apparent increase in pancreatic 
endocrine mass and led to dramatic weight gains and glycaemic tolerance (an 
indirect way of measuring blood glucose at the time) [66-68J. Unfortunately, the 
benefits of this surgical manipulation were short-lived and most patients reverted 
to pre-surgery conditions in approximately 18 months. 
1.3.2.2 Pancreas Transplantation 
Currently, pancreas transplantation is the only effective means of achieving 
long-term stringent glycaemic control in diabetic individuals [64J. This therapy has 
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even been shown to lead to the reversai of pre-existing diabetic complications 
[64]. Unfortunately, an absolute requirement of this therapy is continuai 
immunosuppression, which can lead to a multitude of secondary side effects. 
Furthermore, the paucity of organ donors and the invasiveness of the procedure 
prevent this therapy from reaching a significant number of individuals with 
diabetes. 
1.3.2.3 Islet transplantation 
Islet transplantation was pioneered to address the problems associated 
with whole organ transplantation. It was hypothesized that a pancreas contains 
more than enough islets to maintain normoglycaemia following the observations 
that patients who underwent partial pancreatectomy were still euglycaemic and 
that clinically observed type 1 diabetes occurred only when greater than 50% of 
islets were destroyed [7]. Therefore, multiple recipients could benefit from the 
pancreatic islets isolated from a single organ instead of treating only one patient 
as occurs with whole organ transplant. Furthermore, the suggestion that the 
exocrine portion of the pancreas was responsible for most of the immune 
response following whole organ transplantation, led to the initial belief that 
immunosuppression may not be required or could be drastically reduced, in the 
setting of isolated islet transplantation. 
The initial results of the Edmonton Protocol released in 2000, suggested 
that islet transplantation could be a viable therapeutic alternative for diabetic 
individuals [69, 70]. Unfortunately, however, these procedures proved to be more 
beneficial in theory rather than in practice. In almost ail cases, multiple pancreatic 
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donors and transplantation procedures were required to achieve insulin-
independence and patients still required chronic immunosuppression. The 
procedure, while less invasive than whole organ transplantation, still results in 
significant physical damage [71, 72]. Furthermore, the liver is a suboptimal 
transplantation site that exposes islets to very high concentrations of 
immunosuppressive agents, which are known to be ~-cell cytotoxic [73]. The 
most significant shortcoming of islet transplantation is that the average patient 
requires exogenous insulin administration after about 15 months post-transplant, 
versus approximately 10 years for whole organ transplant [64, 72). 
Clearly new treatment paradigms are needed to achieve normoglycaemia 
and prevent complications associated with diabetes mellitus. Restoration of a 
glucose-responsive islet cell mass through islet and whole pancreas 
transplantation has allowed people with diabetes to achieve normoglycaemia 
without an increased frequency of hypoglycaemia [74]. However, lack of 
adequate transplantable tissue, graft rejection, surgical invasiveness and disease 
recurrence prevent pancreas and islet transplantation from being a viable therapy 
for the majority of people with diabetes [72, 74, 75]. A potential therapeutic 
alternative that may address the insufficiencies inherent to transplantation therapy 
is the stimulation of endogenous ~-cell mass expansion. 
1.4 ~-CELL MASS DYNAMICS 
Like virtually ail tissues of the body the ~-cell mass is dynamic [76-79]. 
The number of ~-cells can be increased by increasing the rate of new ~-cell 
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formation and by decreasing the rate of j3-cell loss [79]. New j3-cell formation can 
occur through replication of pre-existing j3-cells (hyperplasia) as weil as through 
the formation of new j3-cells from non-j3-cells (neogenesis). j3-cell mass can also 
be expanded through increased individual j3-cell size (hypertrophy). Alternatively, 
a reduction in j3-cell hyperplasia, neogenesis, cellular volume (atrophy) and an 
increase in j3-cell death can le ad to a reduction in the number of j3-cells and a 
smaller j3-cell mass. In addition, j3-cell mass may be reduced by a loss of j3-cell 
phenotypic stability [80, 81]. 
1.5 DEFINITION OF ISLET NEOGENESIS 
Islet neogenesis, or more specifically j3-cell neogenesis is the formation of 
a new insulin-producing j3-cell from a non-insulin-producing progenitor. Islet 
neogenesis occurs when newly formed j3-cells cluster together and join with other 
newly formed endocrine cells. Until very recently it has been impossible to 
perform in vivo cellular lineage tracing experiments to unequivocally determine the 
mechanism of new j3-cell and islet formation within the pancreas [82]. In the past, 
a histological categorization was developed to identify j3-cells thought to be newly 
forming from non-insulin-producing progenitors [34, 37, 83-88]. j3-cells were 
categorized as being neogenic if they both contained insulin and were situated 
outside of a fully-formed islet of Langerhans. These extra-islet j3-cells are usually 
adjacent to pancreatic duct cells or located within a pancreatic acinus (Figure 1.3) 
[37, 85-87, 89, 90]. It is theoretically possible, however unlikely, that these extra-
islet j3-cells initially formed within a mature islet and subsequently migrated to an 
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Figure 1.3: Histological representations of islet neogenesis. (A) A 
photomicrograph of a pancreatic section stained for insulin (brown) in which there 
is an extra-islet acinar-associated J3-cell. and (8) extra-islet duct-associated 13-
cells. (bar = 1 0 ~m) 
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extra-islet location. Nevertheless, here the term ~-cell neogenesis will refer to the 
formation of these extra-islet ~-cells. Advancements in the study of pancreatic 
ontogeny has facilitated the understanding of the histological classification system 
and provided insight to the critical elements of new ~-cell formation. 
1.6 PANCREATIC ONTOGENY 
During pancreatic ontogeny, ~-cell mass dramatically increases through 
the mechanisms of cell dynamics described above [88, 91-94]. Critical analyses 
of pancreatic ontogeny have identified many cellular factors that may be involved 
in progenitor differentiation and subsequent ~-cell mass expansion. 
As described previously, the human pancreas is made up of endocrine, 
acinar, and duct cell types. Pancreatic organogenesis begins with dorsal and 
ventral protrusions of a region of the primitive gut epithelium (Figure 1.4) [91, 95, 
96]. Subsequently, the upper foregut endoderm gives ri se to the distinct 
pancreatic cell types [94, 97, 98]. Early steps controlling the commitment of the 
gut epithelium towards a pancreatic fate, as weil as the mechanisms underlying 
the development of the different pancreatic cell types, however, are not weil 
understood. 
Several homeodomain and basic helix-Ioop-helix (bHLH) transcription 
factors, notably Is11, Nkx2.2, Pax4, Pax6 and NeuroD/BETA2, have been shown 
to play an important role in the process of pancreatic endocrine cell differentiation 
[94, 97, 98]. These factors are expressed at early stages of pancreas 
development, but in their absence, the initial steps of pancreatic development 
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Figure 1.4: Pancreatic ontogeny. (A) Illustration of the budding of primordial gut 
endothelium and tissue maturation during pancreatic organogenesis. (8) Key 
factors expressed during this morphological transformation. 
(A) morphological illustration excerpted trom, Pictet RL & Rutter K Handbook of Physiology, 
1972. 
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differentiated 
cell types 
proceed normally resulting with later disruption of pancreatic endocrine cell 
differentiation [94, 97, 98]. In contrast to the above mentioned factors, 
transcription factor p48, which is required for the generation of exocrine but not 
endocrine cells [99], and the homeodomain protein PDX-1, are required at an 
earlier stage in pancreatic development [100-103]. Later stages of pancreatic 
development, particularly the branching morphogenesis and exocrine 
differentiation depend on other factors, including Isl1 and NeuroD/BETA2 [104]. 
While both Isl1 and NeuroD/BETA2 are expressed in ail differentiated 
pancreatic endocrine cells as they develop, neither gene seems to function as a 
bon a {ide pro-endocrine gene [97], a role that may possibly be attributed to the 
gene neuragenin-3 (NGN-3) [105]. Evidence suggests that notch signalling 
controls the choice between differentiated endocrine and exocrine cell fates during 
development by inhibiting NGN-3 [106-109]. High NGN-3 levels occur when notch 
signalling is inhibited resulting in endocrine differentiation. As differentiated 
endocrine cells appear, they separate fram the duct-like epithelium and migrate 
into the adjacent mesenchyme where they cluster to form new islets. Pragenitor 
cells that are not singled out to become endocrine cells will subsequently 
differentiate into either acinar cells or mature ductal cells. 
Analyses of pancreatic ontogeny have led to greater understanding of islet 
neogenesis and t3-cell mass expansion during embryology, but these mechanisms 
may differ in the adult pancreas. Research into the pathways and animal models 
of pancreatic regeneration has shed light on the potential mechanisms leading to 
t3-cell mass expansion in the adult. 
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1.7 PATHWAYS OF PANCREATIC REGENERATION 
As previously described, a possible alternative to islet and pancreas 
transplantation is the induction of new islet cell growth from endogenous 
progenitors. There are three potential pathways for endogenous ~-cell expansion. 
These pathways are: the proliferation of pre-existing ~-cells, the activation and 
differentiation of stem cells, and the nuclear reprogramming of fully differentiated 
cells into new cerI phenotypes (transdifferentiation). 
1.7. 1 Replication of Pre-Existing f3-cells 
Adult human pancreatic ~-cells generally do not replicate at a high rate, 
thereby limiting the usefulness of ~-cell hyperplasia as a means of endogenous ~­
cell mass expansion. Both in vivo and in vitro studies of ~-cell replication have 
shown that very few ~-cells are proliferating at a given point in time [12, 37, 110, 
111 J. Furthermore, stimulating ~-cell hyperplasia in vitro results not only in 
moderate ~-cell proliferation but also in decreased insulin content and endocrine 
function [110]. The balance between endocrine function and proliferative capacity 
has also been observed in vivo in animal models of ~-cell stress [89, 112, 113]. 
ln 2004, Dor et al. hypothesized that endogenous pancreatic ~-cell 
regeneration in adults occurred only through ~ -cell hyperplasia [82]. 
Unfortunately, the experiments that supported this hypothesis were performed in 
mice, which have been shown to have a much higher ~-cell proliferative potential 
than humans [11, 78, 114]. Other researchers tried to confirm Dor et al.'s initial 
findings, but they could not, indicating that alternative mechanisms of ~-cell 
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expansion may contribute to regeneration in this model [115]. Thus, while ~-cell 
replication can le ad to an increase in ~-cell number in rodents, it appears that this 
mechanism of expansion may not be the most effective means of endogenous ~­
cell mass expansion in humans. 
1.7.2 Stem Cell Activation and Differentiation 
Stem cells are defined as cells that are capable of undergoing self-renewal 
and multi-lineage differentiation [116]. Stem cells can be classified according to 
their regenerative potential as being totipotent, pluripotent, multipotent or 
unipotent. A totipotent stem cell can give rise to a complete offspring including the 
placental components, whereas a pluripotent stem cell has the capability to form 
ail of the organs of the offspring only. Multipotent stem cells can form more than 
one cell lineage, however the different possible lineages are usually closely 
related [43, 117]. Multipotent stem cells have also been categorized as tissue-
specific stem cells (TSC). 
There is a lot of controversy regarding the existence of pancreatic stem 
cells [25, 82, 118, 119]. Pancreatic stem cells could be utilized towards 
regenerating endogenous ~-cell mass, though positively identifying them remains 
a problem. Currently, the most effective means of identitying cell types is through 
immunohistochemical analysis. Given that stem cells are dynamic cells that 
change their phenotype as they differentiate, it is difficult to identify pancreatic 
stem cells in vivo based solely on immunohistochemical techniques. Clonai 
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analyses of rodent pancreatic extracts have indicated that multipotent stem cells 
reside within the pancreas, though their exact location is unknown [118]. 
Another strategy for the categorization of progenitors cells is to describe 
cells in regards to their degree of regenerative-competence. It has become 
increasingly apparent that cellular differentiation can be stimulated through the 
orchestration of specifie growth factors and extracellular matrix [120]. Depending 
on the prevailing cellular environment, ail cells possess various degrees of 
regenerative competence [120-124]. By extension, the differentiation potential of 
cells can drastically change depending on these specifie microenvironments, and 
this can pose problems in experimental reproducibility. If the proper 
microenvironment can be arranged, it may allow for a mature and terminally 
differentiated cell to be transformed into a different cell phenotype. 
1.7.3 Transdifferentiation 
Recent studies have indicated that fully differentiated cells contain a 
degree of phenotype plasticity [125-127]. Stimulation of mature cells can lead to 
phenotypic transformation in multiple settings [115, 126-129]. This terminal cell 
transdifferentiation can occur through two separate pathways [126, 127, 130]. 
Direct transdifferentiation occurs when a cell transforms into a phenotypically 
different cell without passage through an intermediate non-specifie cell phenotype 
and without the requirement of replication [80, 127]. The second, indirect 
pathway, consists of transdifferentiation through a process of cellular 
dedifferentiation to a more primordial cell phenotype, followed by proliferation, and 
subsequent redifferentiation into a new mature cellular phenotype [25, 75, 89, 
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126]. Even though indirect transdifferentiation is more predominant during 
development than direct transdifferentiation, both of these mechanisms may be 
active in the adult pancreas and capable of leading to endogenous j3-cell 
expansion [25, 80, 127]. Since transdifferentiation can involve the transformation 
of mature fully differentiated cells, any of the non-j3-cell phenotypes of the adult 
pancreas can be viewed as a potential source for endogenous j3-cell expansion. 
1.7.3.1 Duct Transdifferentiation 
Several lines of evidence suggest that duct cells are the progenitor cells 
that transdifferentiate into both endocrine and exocrine pancreatic tissue during 
fetal development [88, 92, 131, 132]. This assumption is based on morphological 
observations as weil as duct cell replication analyses. Duct cell replication indices 
are high relative to other tissue types during early fetal development, suggesting 
that transdifferentiation of duct cells contributes to endocrine and exocrine growth 
[88, 92]. Further support for the transdifferentiation of duct cells cornes from 
observations of cells with mixed phenotypes during fetal and neonatal 
development [88, 92]. Early endocrine cells are found to express both insu lin and 
the duct cell specific marker, cytokeratin, when j3-cell mass is dramatically 
increasing and duct cell replication rates are elevated [92]. These findings 
suggest that these cells co-expressing both duct and endocrine markers are in the 
process of duct-to-j3-cell transdifferentiation [88, 90, 92, 133]. 
Histological evidence of duct-to-j3-cell transdifferentiation has also been 
observed in the adult pancreas. Single insulin positive cells bordering the duct 
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lumen have been identified in the adult pancreas, suggestive of duct-to-j3-cell 
transdifferentiation (Figure 1.38) [37, 86, 133, 134]. Small duct like structures 
have also been observed to appear from mature ductal elements (main and large 
pancreatic ducts) raising the possibility that indirect transdifferentiation may also 
occur from duct cells [135]. In summation, these observations suggest that both 
direct and indirect duct cell transdifferentiation can lead to new islet formation in 
the normal and regenerating adult pancreas. 
1.7.3.2 Acinar Transdifferentiation 
Researchers of exocrine pancreatic disease are weil aware that the acinar 
tissue contains the dramatic potential to transdifferentiate in various pathological 
settings [20, 128]. More recently, researchers of endocrine pancreatic biology 
have become interested in the potential for acini to transdifferentiate, especially 
towards a j3-cell fate [89, 115, 128, 136-138J. 
ln cases of chronic pancreatitis and pancreatic adenocarcinoma, patients 
can develop obstruction of the pancreatic ductal network, which leads to leukocyte 
infiltration and changes in extracellular matrices and levels of growth factors. 
These conditions are thought to facilitate the transdifferentiation of pancreatic 
acini into tubular duct-like structures, a process known as acinoductal metaplasia 
[128J. The cells of these newly formed tubular complexes are generally more 
proliferative and primordial in both phenotype and genotype th an normal exocrine 
cells [128J. ft is hypothesized that the cells of these tubular complexes give rise 
to, or potentiate pre-existing, pancreatic adenocarcinoma [128}. Recent in vitro 
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cell lineage studies have indicated that this apparent acinar-to-duct 
transdifferentiation is indeed a transformation of cell phenotype and not simply the 
proliferation of pre-existing ductal elements [129]. It has also been hypothesized 
that the cells of these newly formed tubular complexes contain the potential to 
transform into insulin-producing ~-cells [89, 128, 136, 138]. Thus, a possible 
avenue for increasing the endogenous ~ -cell mass is the indirect 
transdifferentiation of acini that begins with the transformation of adult pancreatic 
acini into duct-like structures, followed by their redifferentiation to an endocrine 
phenotype. 
ln addition to indirect transdifferentiation, direct acinar-to-~-cell 
transdifferentiation could expand the ~-cell. Less is currently known about direct 
transdifferentiation of acinar cells into endocrine cells, though it has been 
suggested to occur both in vivo and in vitro [89, 139-141]. Co-Iocalization 
analyses of acinar and endocrine factors, similar to that performed in mixed duct 
and endocrine cell phenotypes have indicated that these cells exist and that they 
have the potential to increase the en doge nous ~-cell mass. 
1.7.3.3 Endocrine Transdifferentiation 
During pancreatic ontogeny cells co-expressing glucagon and insulin are 
among the first endocrine cells to develop [93, 142]. Recent transgenic studies 
have questioned whether the co-Iocalization of insulin and glucagon protein in 
pancreatic progenitor cells is due to a technical anomaly [143]. Herrara et al. 
indicate that endocrine-to-endocrine transdifferentiation does occur during 
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pancreatic development, although it is pancreatic polypeptide producing cells and 
not glucagon expressing cells that co-Iocalize insulin [143]. Furthermore, the 
transdifferentiation of somatostatin producing ô-cells into insulin-producing ~-cells 
has been observed during islet regeneration in neonatal rats [144]. These 
observations suggest that direct transdifferentiation of pre-existing endocrine cell 
phenotypes into insulin-producing ~-cells is a possible means for increasing 
endogenous ~-cell mass. 
Recently, the morphological plasticity of adult pancreatic islets has also 
been indicated [81, 125, 145, 146]. Mature adult islets appear to contain the 
potential to transdifferentiate into duct-like structures, both in vivo and in vitro [81, 
125, 145, 146]. These islet-derived duct-like structures are highly proliferative and 
have been shown to contain the potential to re-form islet-like structures [125]. The 
exact mechanism of this transformation is yet to be fully elucidated but in vitro 
studies indicate that changes in integrin as weil as other growth factor and cAMP 
signalling pathways stimulate the initial differentiation into duct-like cells [80, 81, 
147-149]. The redifferentiation of these islet-derived duct-like structures into 
endocrine cells appears to involve duct-to-endocrine differentiation [125]. This 
indirect transdifferentiation pathway has the potential to increase ~-cell mass 
through the expansion of the primordial duct-like structures prior to their 
redifferentiation back to islet-like structures. 
It is thus apparent that ail three major cell types of the adult pancreas have 
the capability to lead to an increased endogenous ~-cell mass through both direct 
and indirect transdifferentiation processes. A closer look into current in vivo 
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paradigms of pancreatic regeneration and ~-cell neogenesis will provide insight to 
the potential of these various pathways in expanding endogenous ~-cell mass in 
the adult pancreas. 
1.8 MODELS OF PANCREATIC PLASTICITY AND REGENERATION 
1.8.1 Partial Duct Obstruction 
Partial duct obstruction, achieved through the wrapping of the duodenal 
portion of the pancreas with cellophane tape, is a surgical procedure associated 
with islet expansion [85, 133, 134, 150, 151]. Partial duct obstruction results in 
periductal fibrosis without diffuse pancreatitis. This surgical manipulation is 
associated with both duct cell hyperplasia and islet cell neogenesis [85]. The 
increase in ~-cell mass that follows partial duct obstruction appears to be via the 
differentiation of duct-associated progenitor cells and not as a result of the 
replication of pre-existing ~-cells [152]. Following the analysis of tritiated 
thymidine labelling in partially duct obstructed hamsters, it was suggested that 
duct-to-~-cell transdifferentiation was taking place. Tritiated thymidine 
administered in a single dose 2 weeks following partial duct obstruction was 
initially incorporated into .... 2.5% of duct cells and 0.4% of endocrine cells. Six 
weeks later, islet cell labelling was 1.4% suggestive of an initial incorporation of 
tritiated thymidine into duct cells and subsequent differentiation of these duct cells 
into endocrine cells [153]. The observation of duct-associated, small endocrine 
clusters budding from the ductal epithelium supported the authors conclusions of 
duct-to-~-cell transdifferentiation [154]. 
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Next, Rosenberg et al. sought to determine the underlying factor(s) for this 
observed islet neogenesis and subsequent ~-cell mass expansion. Using an 
eloquent study entailing parabiosis, it was demonstrated that a paracrine agent 
produced by the wrapped portion of the pancreas was responsible for this 
elevated duct-cell proliferation and islet neogenesis [155]. A cytosolic extract, 
termed ilotropin, was then prepared from partially duct obstructed pancreases and 
administered to hamsters. lIotropin administration resulted in increased new ~-cell 
formation through the replication and differentiation of ductal precursors cells [151, 
152, 155]. lIotropin has also been used to reverse streptozotocin (STZ) induced 
diabetes in hamsters [156]. 
A Reg3 gene was found to be upregulated in partially duct obstructed 
pancreases through differential display analysis, and upon further purification of 
ilotropin, the Reg3 protein was identified [157, 158]. This specific hamster Reg3 
protein appeared to contain the growth potentiating effects of ilotropin and was 
termed islet neogenesis associated protein (INGAP) [158]. When in situ 
hybridization was performed on pancreatic sections from partially duct obstructed 
hamsters, INGAP was found to be expressed in acinar cells 1 to 2 days following 
cellophane wrapping. This led to the suggestion that INGAP may be directly 
associated with the ~-cell mass expansion observed in this setting [158]. 
Antibodies directed against the amino acid sequence in the central core of the 
protein (comprising amino acids 104-118) abolished the trophic actions of the 
ilotropin extract suggesting that this pentadecapeptide region contained the 
biological activity of this protein [158]. These results suggested that the pancreas 
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contains an inherent system to exp and ~-cell mass through new islet formation, 
and that the exogenous administration of this pancreas specific growth factor 
could lead to islet neogenesis and ~-cell mass expansion. 
1.8.2 Partial Pancreatectomy 
Pancreatic regeneration has been observed following removal of 90 to 95% 
of the pancreas in normal young (5 to 6 weeks old) rats. The remnant pancreas 
grows to approximately 30% of the pancreatic mass of non-operated animais 
[135]. During this regeneration, sm ail ductal structures (tubular complexes) 
appear approximately 36 hours after surgery and comprise up to 9% of the 
pancreas volume 48 hours after surgery [135]. By 7 days post-surgery, these 
tubular complexes are rarely detected [135]. Tubular complexes observed in 
these animais are thought to be neogenic due to the high replication of the 
constituent duct cells along with their coincidental appearance and disappearance 
with the marked growth of the pancreatic remnant [135]. 
Bonner-Weir et al. suggested that cells of the main pancreatic duct are 
responsible for the rise of these tubular complexes, and thus the regenerative 
response, following partial pancreatectomy [135]. It was demonstrated that the 90 
to 95% partial pancreatectomy led to successive waves of duct ce" proliferation, 
beginning in larger mature ducts and culminating in the duct cells found in the 
tubular complexes [135]. Common and main duct cells reached a peak replication 
index 36 hours after pancreatectomy, then sm ail duct cells at 48 hours, and 
tubular complex duct cells at 72 hours after pancreatectomy. These data suggest 
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that proliferation and differentiation of duct cells gives rise to tubular complexes 
that subsequently differentiate into endocrine and exocrine tissue in this setting of 
pancreatic regeneration [135]. 
Regeneration following partial pancreatectomy has been proposed to occur 
through a recapitulation of embryonic development. The elevated duct cell 
labelling index followed by an increased J3-cell mass is similar to that seen during 
pancreatic ontogeny. Likewise, tubular complexes observed following partial 
pancreatectomy appear similar to the morphology of fetal pancreases. Key 
factors in the embryological development of the endocrine pancreas are 
upregulated in partially pancreatectomized rodents. PDX-1 is observed to be 
upregulated in duct cells 2 to 3 days after partial pancreatectomy [159]. Gastrin, a 
growth factor that influences the expansion of endocrine cells during late fetal 
development is also believed to be critical during this regenerative period [137, 
160]. Other pro-endocrine factors including the incretin GLP-1 and members of 
the Reg family are associated with regeneration in partially pancreatectomized 
rats [161, 162]. Together, these studies suggest that the young adult rat pancreas 
can increase J3-cell mass in a manner similar to the J3-cell mass expansion that 
occurs during organogenesis. 
1.8.3 Pancreatic Duct Ugation 
Complete pancreatic duct ligation is another surgical method used to 
initiate regeneration of the pancreas. Similar to partial pancreatectomy, tubular 
complexes form, though in duct ligation normal acinar tissue is replaced with 
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tubular complexes associated with surrounding lymphocyte infiltration [86, 137, 
138, 163]. Neogenesis occurs in pancreatic duct ligated animais as indicated by 
the appearance of tubular complexes and small duct-associated islets du ring the 
rapid expansion of the (3-cell mass. 
Wang et al. suggested that duct cells are the progenitor cells that give rise 
to the (3-cell mass expansion following ligation. Duct cell replication indices 
increased by 10-fold to a maximum 18% in the ligated portion of the pancreas 3 
days post-surgery [86]. In contrast, the (3-cell replication index peaked later, at 7 
days post surgery, similar to that observed by Rosenberg et al. [150, 153]. These 
results suggest that duct to (3-cell transdifferentiation contributes to the increased 
(3-cell mass observed in the ligated portion of the pancreas. 
The regenerative response observed during pancreatic duct ligation is 
associated with the upregulation of multiple growth factors. Similar to what occurs 
following partial pancreatectomy, cytokines and growth factors, including 
transforming growth factor alpha (TGFa) and gastrin, are upregulated in the 
ligated portion of the pancreas [163]. TGFa, an epidermal growth factor analog, is 
produced by macrophages, pancreatic ducts and islet cells [163-165], and can 
stimulate duct cell proliferation and differentiation [137, 160]. The interaction of 
TGFa and gastrin is thought to initiate the tubular complex formation and the 
neogenic response in pancreatic duct ligated animais. 
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1.8.4 Glucose Infusion 
Excessive metabolic supply, specifically through chronic infusion of 
glucose, results in an increased demand for insulin [166]. Administration of 
glucose to rats leads to expansion of the f3-cell mass through f3-cell hypertrophy 
and hyperplasia [166]. When Finegood et al. pertormed a mathematically based 
analysis of the f3-cell mass dynamics of rats infused with glucose for up to 6 days, 
they found that the increased f3-cell hyperplasia and hypertrophy could not 
account for the observed increase in f3-cell mass [89, 113]. Thus, it was predicted 
that f3-cell neogenesis must be partially responsible for the expansion of the f3-cell 
mass in this model. 
A quantitative analysis of f3-cell mass dynamics led to the discovery of 
increased neogenic f3-cell mass with chronic glucose infusion [89J. There was an 
increase in single extra-islet f3-cells associated with acinar tissue and a large 
number associated with newly formed tubular complexes [89J. An analysis of 
CD3+ cells, revealed a wave of T-cell infiltration into acinar lobes prior to the 
development of the tubular complexes. The authors concluded that this T -ce Il 
infiltration led to the acinoductal metaplasia, which subsequently resulted in the 
increase in extra-islet f3-cells associated with these structures [89J. These findings 
suggest that in the setting of chronic glucose infusion either direct acinar-to-f3-cell 
transdifferentiation or indirect acinar-to-duct-to-f3-cell transdifferentiation could 
lead to an expanded endogenous f3-cell mass [89J. 
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1.8.5 f3-Cell Toxin - Streptozotocin 
Streptozotocin (STZ) is a cytotoxic gluconitrosourea that is translocated 
across the cell membrane by GLUT-2, though negligibly by other glucose 
transporters and thus, preferentially affects ~-cells [167]. Administration of a high 
dose of streptozotocin (200 mg/kg·bw) to young rats results in the destruction of 
nearly ail ~-cells [144). This initial wave of ~-cell death is followed by a .... 3-fold 
increase in PDX-1 expression in somatostatin producing ô-cells [144). As PDX-1 
is a key regulator of the insulin gene, the observation of PDX-1/somatostatin 
double positive cells is suggestive of the transdifferentiation of ô-cells to a ~-cell 
phenotype. Consistent with this interpretation, Fernandes et al. observed triple 
positive somatostatin/PDX-1/insulin cells following the increase in double positive 
somatostatin/PDX-1 ce Ils [144). This study indicated that, at least in young rats, 
another source for new ~ -cell formation is direct endocrine-to-endocrine 
transdifferentiation. 
1.8.6 Transgenic Mice 
Transgenic mice, over-expressing interferon gamma (IFNy) under the 
control of the human insulin promoter, have also been used to delineate potential 
regenerative pathways in adult mice. Initially, IFNy causes an immune response 
leading to extensive ~-cell destruction [168, 169]. In areas of immune cell 
infiltration, sm ail duct structures form that are similar to previously described 
tubular complexes [170]. Through analyses of BrdU (a thymidine analog) 
incorporation into duct and ~-cells, Gu et al. suggest that newly formed ~-cells 
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observed in these animais, originate from the transdifferentiation of these 
dedifferentiated ductal cells. As weil, they conclude that over-expression of IFNy 
attracts leukocytes leading to the local upregulation of TGFa and epithelial growth 
factor (EGF). This elevation in growth factors subsequently leads to the 
differentiation of acinar cells into tubular complexes that give rise to new t3-cells, 
similar to that observed in other instances of pancreatic regeneration [160, 163, 
171,172]. 
The growth potentiating effects of TGFa and gastrin were further defined 
through analyses of transgenic mice, which over-expressed TG Fa under the 
control of the metallothionein-1 promoter, and gastrin, under the control of the rat 
insulin-1 promoter [160]. Over-expressing TG Fa in acinar cells leads to a 
dramatic transformation of the pancreatic acini [160, 173, 174]. A majority of the 
acini transform into tubular complexes similar to that observed in partial 
pancreatectomized and duct ligated rats. In addition, there is an increase in duct 
cell replication in these mice, though there is no increase in t3-cell mass [160, 173, 
174]. Similarly, mice over-expressing gastrin in t3-cells do not have an increased 
t3-cell mass [160]. However, when these two strains of mice are crossed, and 
both TGFa and gastrin are over-expressed, t3-cell mass doubles [160]. These 
results suggest that indeed t3-cell mass is controlled by the interaction of cytokines 
and growth factors upregulated in the context of pancreatic regeneration. 
The aforementioned in vivo models of pancreatic regeneration have 
indicated that two major pathways, direct duct transdifferentiation and indirect 
acinar transdifferentiation, lead to endogenous t3-cell mass expansion in a number 
Page 38 
of settings. As weil, these studies have indicated a number of factors that appear 
to be involved in the regeneration of the adult pancreas, and imply that the 
administration of these factors could lead to endogenous ~-cell mass expansion. 
1.9 MOLECULAR FACTORS ASSOCIATED WITH PANCREATIC 
REGENERATION 
1.9.1 Regenerating Pro teins (Regs) 
The Reg family of proteins is composed of members identified in different 
settings of pancreatic disease and regeneration [158, 175-182]. As such, various 
nomenclatures arose identifying these proteins [183, 184]. The first factor to be 
identified was termed pancreatic stone protein (PSP) as it was associated with the 
formation of pancreatic stones during chronic pancreatitis [185]. PSP was again 
identified by a different group and termed pancreatic thread protein (PTP) and yet 
again by another group who designated it lithostatine, as it could be used to block 
the formation of calcium carbonate crystals [185, 186]. Watanabe et al. also later 
identified this same factor from the cDNA of regenerating islets and termed it 
Reg1 [182]. Since these initial observations, researchers have now identified four 
major types of Reg proteins (Reg1, 2, 3, and 4). Reg1 and Reg4 have been 
associated with gastric cancers [176, 178], while a Reg member has been found 
to be upregulated during the early insulitis and regenerative phases in Bio 
Breeding rats [187, 188). Additionally, Reg upregulation is observed in multiple 
models of pancreatic regeneration including partial duct obstruction, partial 
pancreatectomy and glucose infusion, further indicating that Regs are key factors 
of pancreatic regeneration in the adult [162, 188, 189). 
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A multitude of functions have been ascribed to Reg proteins. Reg proteins 
posses aC-type lectin-like domain motif suggestive of carbohydrate binding 
activity [184, 190). This has been confirmed though studies of both human Reg3a 
and mouse Reg3y binding lactose and mannose respectively [191, 192). 
Furthermore, Reg3a has been indicated to play a role in cell migration and 
adhesion in hepatocytes, whereas Reg1 has been implicated in the regulation of 
intestinal bacteria through the promotion of binding and aggregation within the 
intestine [193, 194]. Regs have also been associated with tissue regeneration, 
with Reg3 members showing anti-apoptotic activity as weil as inhibition of cellular 
inflammation [195, 196]. This association with tissue regeneration has also been 
suggested as Reg1 and Reg3 have been shown to stimulate pancreatic duct cell, 
intestinal cell and Schwann cell replication [158, 197-200). 
As described earlier, INGAP, a hamster Reg3 protein, appears to have 
potential in stimulating endogenous islet neogenesis. The identification of the 
pentadecapeptide fragment (INGAp104-118) that contains similar biological activity 
as the full length protein, may enable a simpler therapeutic option for the 
expansion of endogenous ~-cell mass. The observations of the in vivo 
effectiveness of ilotropin and the in vitro effects of INGAp104-118 to stimulate duct 
cell proliferation, suggest that there is potential in the pharmacological 
administration of this compound to stimulate new ~-cell formation in individuals 
with diabetes [158). 
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1.9.2 Combination: EGF and Gastrin 
As discussed previously, Wang et al. observed that over-expression of 
TGFa and gastrin in mice led to significant f3-cell mass expansion [160]. In a 
subsequent study these factors were administered exogenously to 
hyperglycaemic rats resulting in a significant reduction in blood glucose levels 
(,..,20 vs. ,..,30 mmol/I) [171]. Correspondingly, f3-cell mass was significantly 
increased in mice treated with EGF and gastrin, though only to approximately one 
tenth that of normoglycaemic controls. 
These initial findings have been furthered by Suarez-Pinzon et al. using 
non-obese diabetic (NOD) mice, which are a rodent model of type 1 diabetes 
[201]. Administration of EGF and gastrin led to amelioration of hyperglycaemia in 
5 of the 6 treated mice and f3-cell mass was four-fold greater than at the start of 
the experiment. Unfortunately, this mouse model is inherently problematic with 
regards to reproducibility and treatment specifie effects. More than 100 various 
therapies, including some that seem inert, have reversed diabetes in NOD mice 
[202]. Despite this drawback, the combination EGF-gastrin therapy reported by 
Suarez-Pinzon et al. led to significant beneficial changes when compared to 
appropriate experimental controls. 
Furthermore, EGF and gastrin combination therapy has been used to 
greatly expand the insulin content in mixed cultures of human islet and duct tissue 
[203]. EGF and gastrin therapy led to dramatic increases in CK19 positivity as 
weil as PDX-1 upregulation, along with an approximate doubling of insulin content. 
When severely combined immunodeficient (scid) NOD mice were transplanted 
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with human islets, EGF and gastrin therapy was found to enhance the insulin 
content of these transplanted islets versus saline controls [203]. These results 
suggest that islet expansion both post-isolation in vitro and post-transplantation in 
vivo can be achieved via EGF and gastrin combination therapy. This treatment 
could dramatically increase the effective yields of current islet isolation! 
transplantation therapies. 
A potential drawback to this line of therapy is the fact that both EGF and 
gastrin are carcinogens [128, 204-206]. Recently, this has been partially 
addressed with the substitution of EGF with the incretin GLP-1, in addition to 
devising gastrin analogs with potentially less carcinogenic activity (Alex 
Rabinovitch, personal communication). As weil as being less carcinogenic, it 
appears that this novel gastrin and GLP-1 combination therapy is equally, if not 
more effective than its predecessor [207]. 
1.9.3 Incretins 
Incretins are proteins produced by the gut in response to nutrient ingestion 
that serve to help regulate nutrient uptake and metabolism [208]. The existence 
of incretins was first postulated from the observation that insulin release was 
much greater following an oral glucose challenge, versus an intravenous glucose 
challenge [208, 209]. Glucose-dependent insulinotropic polypeptide (GIP) was 
identified from gastric extracts that showed heightened insulin release when 
administered to dogs [210]. Brown et al. initially identified GIP in the late 1960s 
from gastric extracts that led to an inhibition of secretion and th us named the 
protein gastric inhibitory polypeptide [211]. Later, when its insulinotropic effects 
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were identified, the name was changed to reflect these findings. GIP potentiates 
the glucose-dependent secretion of insulin release from pancreatic ~-cells. When 
this protein's actions were blocked, an incretin effect was still observed, 
suggesting the presence of other incretins. Glucagon-like peptide-1 (GLP-1) was 
later identified as a second incretin [46,208]. 
Whereas GIP is produced by K-cells of the proximal small intestine, GLP-1 
is produced by L-cells in the distal small intestine and proximal large intestine [46, 
208, 212]. These proteins activate glucose-stimulated insulin release from ~-cells 
through binding to their respective G-protein receptors. This leads to activation of 
cyclic AMP signalling pathways and ultimately increases the intra-cellular calcium 
concentration, which in turn potentiates insulin release [44]. Both proteins are 
rapidly inactivated by dipeptidyl peptidase 4 [46, 208, 212]. 
Since incretins have the potential to increase glucose-stimulated insulin 
release, they have become an attractive avenue for diabetic therapies. As weil, 
ncretins delay gastric emptying and enhance insulin release, which both lead to a 
lower blood glucose profile [46, 208J. These effects can protect pre-existing ~­
cells from glucolipotoxicity directly following meals, when levels of glucose and 
lipids are elevated [13]. Furthermore, there is indication that incretins can act as 
anti-apoptotic agents [47J. Incretins also do not lead to non-glucose stimulated 
insulin release, and therefore hypoglycaemia may not be an issue with this 
therapy. 
It has been suggested that incretins, especially GLP-1, have in vivo islet 
neogenic effects, but appropriate quantification of neogenic ~-cell mass has yet to 
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be performed in such a model [161, 213, 214]. The known actions of GLP-1 
including the potentiating of insulin release, slowing of gastric emptying and 
therefore decreasing metabolic stress, as weil as its potential f3-cell anti-apoptotic 
effects could ail aid in supporting endogenous islet neogenesis. Whether incretins 
are true neogenic agents remains uncertain, though it is clear that they could be 
very effective adjunct agents in the treatment of diabetes mellitus. 
1.9.4 Translation of Factors to Therapy 
As noted above, neogenic agents may have carcinogenic attributes. Both 
EGF and gastrin are well-known epithelial cell carcinogens and the expression of 
Reg1 and Reg4 has been associated with various gastrointestinal cancers [128, 
176, 178, 204-206]. Preliminary evidence suggests that administration of these 
factors could indeed lead to enhanced endocrine regeneration in the pancreas, 
though the carcinogenic potential of these compounds cannot be ignored. 
1.10 PANCREATIC CANCER 
The incidence of adenocarcinoma of the pancreas has risen steadily over 
the past 4 decades. It currently stands at approximately 29,000 new cases per 
year in North America, making it the second most common gastrointestinal 
malignancy and the fifth leading cause of adult deaths from cancer due to its 
aggressive nature [215, 216]. The diagnosis of pancreatic cancer is usually 
established at an advanced stage, and a lack of effective therapies leads to an 
extremely poor prognosis. A meta-analysis of 144 reported studies involving 
approximately 37,000 patients, found the median survival time to be 3 months 
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[217]. According to these findings, 65% of patients with pancreatic cancer will die 
within 6 months from the time of diagnosis, and about 90% will die within 1 year. 
Surgical resection, if performed early enough, is presently the only effective form 
of curative therapy [218]. However, fewer than 15% of patients with pancreatic 
cancer are potential candidates for a curative resection due to metastasis of the 
cancer to adjacent tissues or beyond [219, 220]. The five year survival rate of 
pancreatic adenocarcinoma is 1-4% th us making incidence and mortality rates 
virtually identical [221, 222]. 
Approximately half of ail patients with pancreatic cancer have metastatic 
disease at the time of diagnosis, while the majority of remaining cases have 
locallyadvanced, unresectable disease [223-225]. Metastatic pancreatic cancer 
is one of the most chemotherapy-resistant tumors, as evidenced by the fact that 
pancreatic cancer has the lowest five-year survival rate (3%) of any cancer listed 
in the Surveillance, Epidemiology, and End Results (SEER) data base of the 
National Cancer Institute (NCI). As such, any diabetes therapy that increases the 
incidence of pancreatic adenocarcinoma would not be an optimal therapeutic 
approach. 
There are many similarities between the various models of pancreatic 
regeneration and pancreatic adenocarcinoma. The mechanism of pancreatic 
regeneration and the initiation of tumor formation have been closely associated 
with metaplastic acinar transformation and the upregulation of numerous cell cycle 
and growth factors. If a pharmaceutically induced ~-cell mass expansion therapy 
is to succeed, the potential for inducing unbridled pancreatic cell growth must be 
addressed. 
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1.11 REGULATION OF INDUCED ~-CELL MASS EXPANSION 
Previous studies of endogenous j3-cell mass expansion and involution have 
suggested potential mechanisms that may serve to regulate pharmacologically 
induced j3-cell mass expansion. An intriguing incongruity observed in the 
immediate post-natal period in the rat pancreas, is a remarkably high level of islet 
neogenesis despite a relatively stable j3-cell mass [226]. To gain insight into the 
dynamics of the regulation involved, Finegood et al. developed a mathematical 
model that explained this apparent inconsistency via the simultaneous occurrence 
of islet neogenesis with increased j3-cell apoptosis [79, 226]. Thus, the increase 
in apoptosis, together with minimal levels of j3-cell replication, account for the 
stable j3-cell mass during active l3-cell neogenesis [79, 226]. 
These data support the hypothesis that maintenance of l3-cell mass in the 
post-natal period is an active process in which cell proliferation, differentiation and 
death are involved in the homeostatic regulation of l3-cell mass. Whether there is 
similar homeostatic regulation of j3-cell mass with aging remains to be seen. 
Dynamic control of l3-cell mass in the adult rodent pancreas is suggested 
by studies of pregnancy during which the mother's l3-cell mass greatly expands as 
altered hormone levels increase metabolic demands [227, 228]. Shortly after 
birth, however, the hormonal environment reverts to the non-pregnant state, and 
the expanded j3-cell mass involutes to normal levels through l3-cell atrophy and 
apoptosis and decreased l3-cell replication [228]. Similar cell mass regulation has 
also been reported for lacrimal glands and breast tissue [229-235]. Thus, it 
appears that common control mechanisms in different tissues may serve to align 
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cell mass with functional need. It seems likely, therefore, that such mechanisms 
would also operate in the normal adult pancreas. 
Based on a morphometric analysis of single ~-cells and sm ail ~-cell 
clusters, Bouwens has suggested that islet neogenesis normally occurs in the 
adult human pancreas [37], presumably contributing to the ongoing maintenance 
of ~-cell mass. Neogenesis, however, may be more th an just a basal activity as 
Butler et al. have shown that ~-cell mass expands without increased ~-cell 
replication in cases of obesity [12, 236]. This finding suggests that neogenesis in 
the adult pancreas may respond to alterations in the local microenvironment in the 
setting of obesity. Furthermore, the recent observation that the development of 
type 2 diabetes is correlated with a lack of a neogenic response in adult humans 
suggests that a neogenic therapy may ameliorate this disease (236). 
1.12 RATIONALE 
Diabetes is a devastating disease that affects millions of people. Current 
therapies are not sufficient to prevent the secondary complications of this disease. 
New therapies that mimic the stringent glucose regulation that endogenous islets 
provide are needed in order to better control blood glycaemia levels and prevent 
diabetic complications. Pancreas and islet transplantation is hindered by the lack 
of donor organs and the requirement for harsh immunosuppressive drugs, making 
it an unrealistic therapy for more than 95% of individuals with diabetes. Presently, 
pharmaceutical expansion of endogenous ~-cell mass appears to be the most 
promising therapy for the successful restoration of euglycaemia. 
Page 47 
INGAp104-118 is a promising candidate for the pharmacological induction of 
endogenous l3-cell mass expansion. In order to achieve the therapeutic goal of 
endogenous l3-cell mass expansion and restoration of euglycaemia, however, 
several key issues must be considered. First, it is important to determine if 
endogenous l3-cell mass expansion can be therapeutically induced in animal 
models other th an hamsters, including humans. Furthermore, studies must show 
whether INGAp104-118 can be used to therapeutically reverse diabetic 
hyperglycaemia. Finally, if INGAp104-118 therapy is to be used to clinically treat 
diabetes mellitus, steps must be taken to prove that this is a safe, as weil as 
efficacious, treatment modality. 
1.13 HYPOTHESIS 
INGAp104-118 administration will initiate islet neogenesis and subsequent 13-
cell mass expansion, leading to the reversai of hyperglycaemia in a response that 
is under homeostatic regulation and has efficacy in humans. 
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1.14 OBJECTIVES 
1. Determine if the neogenic agent INGAp104-118 can lead to islet neogenesis 
and ~-cell mass expansion in multiple species. 
2. Determine the cellular mechanism through which INGAp104-118 can reverse 
diabetic hyperglycaemia. 
3. Elucidate the mechanisms involved in the regulation of induced ~-cell mass 
expansion. 
4. Develop a model to test the efficacy of INGAp104-118 in expanding human 
~-cell mass 
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CHAPTER 2 
Pharmaceutical Induction of tl-ce Il Mass Expansion ln Multiple 
Animal Species and Reversai of Diabetic Hyperglycaemia 
Published as: 
Rosenberg L, M Lipsett, J-W Yoon, M Prentki, R Wang, H-S Jun, G L Pittenger, A 
1 Vinik. A pentadecapeptide fragment of islet neogenesis associated protein 
(INGAP) induces ~-cell neogenesis and reverses diabetes in C57BU6J mice. 
Ann Surg. 2004 Nov;240(5):875-84. 
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Doctoral Candidate's Contribution - Manuscript 1 
The doctoral candidate performed administration of scrambled INGAp104-118 
and exendin-4 to diabetic mice as described in this manuscript (Rosenberg et al. 
Ann Surg 2004), though others performed ail additional animal manipulations. 
The doctoral candidate was responsible for: immunohistochemical staining and 
analysis of neogenic j3-cell mass in euglycaemic hamsters administered saline or 
INGAp104-118; immunohistochemical staining and total j3-cell mass determination in 
INGAp104-118-treated CD-1 mice; immunohistochemical staining, j3-cell mass 
distribution and PDX-1 expression in INGAp104-118-treated hyperglycaemic 
C57B16/J mice; combination of ail data gathered; generation of ail figures; ail 
statistical analysis; writing the manuscript. The candidate did not perform the 
collection of the following raw data sets: islet density, total j3-cell mass of 
euglycaemic hamsters, blood insulin and total pancreatic insu lin content in 
euglycaemic hamsters (Rennian Wang, Ann Surg. 2004, depicted in Figures 2.2 
and 2.3), blood glucose determination of diabetic mice (Ji-Wong Yoon, Ann Surg, 
2004, depicted in Figure 2.6). Rennian Wang generated photomicrographs 
depicted in Figure 2.1, and Ji-Wong Yoon generated photomicrographs depicted 
in Figures 2.7 and 2.9. Ali other co-authors contributed in manuscript preparation 
and technical expertise in pancreatic digestions and animal manipulations. The 
doctoral candidate also performed the immunohistochemical staining and analysis 
of total j3-cell mass depicted in figures 2.10, 2.11 and 2.12. 
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2.0 ABSTRACT 
Objective: To demonstrate that INGAp104-118, a pentadecapeptide containing the 
biologically active portion of native INGAP, increases functional J3-cell mass in 
normal animais and can be used therapeutically to reverse hyperglycaemia in 
streptozotocin-induced diabetes. 
Summary Background Data: Islet Neogenesis Associated Protein (INGAP), a 175 
amino acid pancreatic acinar cell protein has been suggested to be implicated in 
J3-cell mass expansion. 
Methods: ln the first part of this study, normoglycaemic hamsters were 
administered either 500 ~g of INGAp104-118 (n=30) or saline (n=20) Lp. daily, and 
sacrificed following 10 or 30 days of treatment. Blood glucose and insulin levels 
were measured and a histological and morphometric analysis of the pancreas was 
performed to determine the effect of INGAp104-118 on the endocrine pancreas. In 
the second part of the study, 6-8 week old C57BL/6J mice (n=8) were 
administered multiple low doses of the J3-cell toxin streptozotocin (STZ) inducing 
insulitis and hyperglycaemia. The mice were then injected with INGAp104-118 (n=4) 
or saline (n=4) for 39 days and sacrificed at 48 days. Two additional groups of 
diabetic mice were administered either a peptide composed of a scrambled 
sequence of amino acids from INGAp104-118 (n=5) or exendin-4 (n=5), an incretin 
that has been associated with amelioration of hyperglycaemia. 
Results: Islet cell neogenesis was stimulated in INGAp104-118-treated hamsters by 
10 days. At 30 days, the foci of new endocrine cells had the appearance of 
mature islets. There was a 75% increase in islet number, with normal circulating 
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levels of blood glucose and insulin. Administration of INGAp104-118 to diabetic mice 
reversed the diabetic state in ail animais, and this was associated with increased 
expression of PDX-1 in duct cells and islet cell neogenesis with a reduction of 
insulitis in the new islets. Diabetic mice treated with exendin-4 or a scrambled 
INGAP peptide did not revert from hyperglycaemia. 
Conclusion: Since there is a deficiency of ~-cell mass in both type-1 and type-2 
diabetes, INGAp104-118 stimulation of fully functional neo-islet differentiation may 
provide a novel approach for a diabetes therapy. 
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2.1 INTRODUCTION 
f3-cell mass is severely reduced in type-1 diabetes, a disease in which a 
progressive autoimmune reaction results in the selective destruction of insulin-
producing f3-cells. Even in type-2 diabetes, the f3-cell mass appears to be reduced 
byas much as 60% of normal [9, 12} and declines by 10-20% per year [10] so that 
f3-cell function is dramatically reduced within 5-10 years of diagnosis. The number 
and size of functioning f3-cells in the pancreas is of critical significance for the 
development, course and outcome of diabetes. Thus the development of diabetes 
can be understood as a failure of adaptive f3-cell growth due to inadequate 
hyperplasia from either insufficient replication of pre-existing f3-cells or neogenesis 
from adult stem/progenitor cells within the pancreas [25, 237]. 
ln the post-natal period, expansion of the pancreatic endocrine cell mass 
manifests itself either by a limited proliferation of the existing terminally 
differentiated islet cells, or by a reiteration of islet neogenesis [75]. In 1983 we 
addressed the notion that induction of islet neogenesis may be a means whereby 
diabetes could be ameliorated [154]. Using a surgical model of partial pancreatic 
duct obstruction (cellophane wrapping of the pancreas), we showed that islet cell 
differentiation from progenitor cells associated with the ductal epithelium could 
indeed be induced in the adult pancreas [85, 152, 153] and that the newly formed 
islets functioned to reverse a diabetic state [151]. Evidence obtained from 
parabiotic studies, in which a common cross-circulation between animais was 
surgically established [155J, suggested that the induction of cell proliferation and 
differentiation was mediated by paracrine and/or autocrine mechanism(s) [155]. 
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Using classical protein chemistry techniques, a soluble tissue fraction was isolated 
from the regenerating pancreas, partially purified and termed ilotropin [157, 238-
240]. This crude extract was shown to reverse streptozotocin-induced diabetes in 
hamsters [156]. Using mRNA differential display [181], we identified, sequenced 
and cloned a novel gene, whose 16.4 kD protein product INGAP (islet neogenesis 
associated protein), was found to be a major constituent of the ilotropin extract 
and appeared to be responsible for the bioactivity of ilotropin [158]. 
To date, only the in vivo effect of the crude pancreatic extract ilotropin, and 
the in vitro activity of INGAP peptide (INGAp104-118) have been examined. We 
demonstrated that the pentadecapeptide is capable of stimulating tritiated 
thymidine eH-TdR) incorporation into the DNA of primary hamster duct cells as 
weil as a rat duct tumor cell line (ARIP), but had no effect on the insulinoma cell 
line HIT-15 [158], suggesting an action on putative stem cells and not on 
terminally differentiated (3-cells. 
Various differentiation factors are required to achieve the mature 
phenotype characteristic of pancreatic (3-cells [91]. Perhaps the most important of 
these is pancreatic duodenal homeobox-1, PDX-1 [91]. In the present study we 
report that INGAp104-118, the putative biologically active portion of native INGAP, 
induces islet cell neogenesis in both normoglycaemic and diabetic animais 
associated with an up-regulation of PDX-1 expression in duct cells. The results 
also indicate that the new islet tissue is hormonally responsive to the prevailing 
metabolic state, and that INGAp104-118 is capable of reversing streptozotocin (STZ) 
-induced diabetes in mice. 
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2.2 MATERIALS AND METHODS 
2.2.1 Preparation of INGAp104-118 
A pentadecapeptide (mw 1501.4) corresponding to amino acids 104-118 
(lle-Gly-Leu-His-Asp-Pro-Ser-His-Gly-Thr-Leu-Pro-Asn-Gly-Ser) of INGAP [158] 
was synthesized at McGiII University. This region of the deduced protein was 
chosen because it has a unique insertion of five amino acids (Ser-His-Gly-Thr-
Leu) compared to Reg/PSP, a related family of genes, and it precedes a potential 
glycosylation site situated at position 126, hence a core of potential biological 
activity [158]. Ali peptides were reconstituted in isotonic saline. 
2.2.2 Stimulation of Islet Cell Neogenesis ln Normoglycaemic Hamsters 
Ali animal studies were performed in accordance with CCAC guidelines. 
Female Syrian hamsters (Charles River, Quebec), 8 weeks of age, were randomly 
allocated to receive daily intra-peritoneal injections of INGAp104.118 (250 f.!g b.Ld.) 
(n=15) or an equivalent volume of saline (n=10) for either 10 or 30 days. This 
species was selected because ail developmental work leading to the discovery of 
INGAP was performed in hamsters [85, 151, 155, 156, 158, 181, 238,239]. The 
INGAp104-118 dose was extrapolated by regression analysis from a pilot study in 
which a recombinant INGAP was demonstrated to reduce blood glucose levels by 
2 mmol/I for each log increase in dose in streptozotocin-treated diabetic hamsters 
[241). Blood glucose was determined on days 0, 3, 6 and 10 using an AccuChek-
EZ glucose monitor (Roche, Indianapolis, Indiana). Plasma and pancreatic levels 
of insulin were determined on day 10. At the end of the study period, animais 
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were anesthetized and sacrificed by exsanguination, and the pancreases excised 
for morphologie and morphometric analysis. 
2.2.3 Dose Response Relationship of INGAp104-118 and fJ-cell Mass 
To examine the dose response relationship between INGAp104-118 and ~­
cell mass, normoglycaemic CD-1 mice 6-8 weeks of age were administered daily 
i.p. injections of 0, 50, 500 or 2500 ~g INGAp104-118 for 34 days (n=10/group). At 
the end of the study period, animais were sacrificed and the pancreases excised 
for morphometric analysis to determine ~-cell mass. 
2.2.4 Treatment of Diabetic C57BU6J Mice with INGAp104-118 
C57SL/6J male mice 6-8 weeks of age (Jackson Laboratories, Cold 
Harbor, ME) were rendered diabetic by intra-peritoneal injection of streptozotocin 
(STZ) in citrate buffer (40 mg/kgobw/day for five consecutive days). Following 
confirmation that ail mice were diabetic (blood glucose greater th an 16.7 mmolll) 
for at least one week, they were randomized to receive daily injections of 
INGAp104-118 (500 ~g, n=4) or an equivalent volume of saline (n=4) for 39 days. 
Slood glucose was determined every 3 days. Ali animais were sacrificed on day 
48 by exsanguination, and the pancreases were excised for morphological 
analysis. 
A second group of animais was rendered diabetic as described above and 
administered scrambled INGAP peptide (Ser-Ser-Thr-Gly-Gly-Gly-Asp-lle-Pro-
Pro-His-Leu-Leu-His-Asn) (500 ~g/day n=5), exendin-4 (Sigma-Aldrich, Oakville, 
Page 57 
Canada) (4 ~g/day, n=5) [161, 242], or an equivalent volume of saline (n=4) for 39 
days. Ali animais were sacrificed on day 48 by exsanguination, and the 
pancreases were excised for morphological analysis. 
2.2.5 Insulin Measurements 
Plasma and pancreatic insulin were measured using a solid-phase 
radioimmunoassay (Immunocorp, Montreal, Quebec). The collected blood was 
centrifuged and the plasma frozen at -70°C until assayed for insulin. A portion of 
each excised pancreas was weighed and then subjected to an overnight acid-
ethanol extraction at 4°C. The cell-free extracts were collected, neutralized with 
0.4 M Tris base and stored at -70°C until being assayed for insulin. 
Determinations were performed in triplicate. 
2.2.6 Microscopy and Morphometric Analysis 
Upon pancreatic excision, each organ was weighed and then fixed in 4% 
paraformaldehyde. Samples were embedded in paraffin and two sections 4 to 5 
~m thick were taken from each pancreas in multiple 1 00 ~m increments and de-
waxed in xylene. Endogenous peroxidase activity was blocked with a 3.0% 
solution of hydrogen peroxide. The sections were washed with PBS and 
incubated with blocking buffer. Siides were stained with one or more primary 
antibodies, including insulin (guinea pig anti-porcine, 1 :750; Dako, Mississauga, 
Canada); a cocktail of antibodies to glucagon, somatostatin, and pancreatic 
polypeptide (rabbit anti-human, 1 :750; Dako); and PDX-1 (1 :750; a generous gift 
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from C. Wright, Vanderbilt University). Slides stained for PDX-1 were incubated 
with citrate buffer for 30 min at 90°C for antigen retrieval before primary antibody 
application. Siides were incubated with primary antibodies overnight at 4°C, then 
washed in PBS and incubated with the appropriate secondary antibody for 1 hour 
at room temperature (1 :500; biotinylated goat anti-guinea pig IgG, or biotinylated 
goat anti-rabbit IgG; Dako). Sections were then washed in PBS, incubated with 
avidin-biotin complexed with horseradish peroxidase (Dako) for 1 hour, and then 
developed using either 3,3'-diaminobenzidine (DAB) tetrahydrochoride (Sigma-
Aldrich) or aminoethyl carbazole (AEC) (Zymed, San Francisco, USA). Ali si ides 
were counterstained with Harris' haematoxylin (Sigma-Aldrich) as described 
previously [87}. A minimum of 2 si ides from each animal for each analysis was 
measured. 
Islet number (per mm2) was determined as previously described [151]. In 
brief, an average of 12 low power microscopie fields was examined per insulin 
immunostained tissue section. Three immunostained slides were analysed for 
each animal. An average of 36 fields was surveyed per pancreas. The number of 
islets (>3 insulin-positive cells) in each field was determined and a mean 
(standardized per mm2 of pancreatic tissue) was then calculated for each 
pancreas. 
To determine j3-cell mass (mg/pancreas), each gland was sectioned along 
its longitudinal axis to avoid any sampling bias due to regional variation in islet 
distribution and cell composition. Islet cross-sectional areas were traced manually 
with the aid of an Olympus BX60 microscope connected by video camera to a 
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computer equipped with Image-Pro Plus software version 4.0 [149J. The total 13-
cell mass was calculated by a stereological equation, as described previously [87J. 
Briefly, islets from insulin stained sections were traced and thresholded using the 
Image-Pro Plus software system to determine stained tissue area. The total 
pancreatic tissue was also measured and a percent J3-cell area was calculated. 
This percent was then multiplied by the excised organ weight to determine the 13-
cell mass. An average of 100 islets was examined in each pancreas. Islet size 
was determined as described by Rosenberg et al. [151]. 
J3-cell neogenesis was analysed as described previously [37, 88-90, 153J. 
Ali insulin-positive clusters of one or more cells were loosely traced and the area 
of the cluster within the trace was determined using the thresholding option. An 
islet was determined to be duct associated if any portion was juxtaposed to a duct. 
Extra-islet acinar associated J3-cells were defined as insulin positive tissue without 
any other associated endocrine cells not juxtaposed to a duct. Duct-associated 
and extra-islet acinar associated J3-cell mass were determined along with the 
percentage of PDX-1 immunopositive duct cells. 
2.2.7 Statistical Analyses 
Comparison between groups was done using a t-test, 1-way ANOVA, or 2-
way ANOVA with post hoc one-tail t-test. Data are presented as mean ± standard 
error of measurement. Significance was accepted at the 5% javel. 
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2.3 RESULTS 
2.3.1 Systemic Effects of INGAp104-118 Injection in Normoglycaemic Hamsters 
Administration of INGAp104-118 (500 Ilg/day) for either 10 or 30 days did not 
effect body weight (data not shown). To determine if INGAp104-118-treated animais 
developed disturbed glucose homeostasis, we measured blood glucose levels 
during the first 10 days of injection, the period when the increase in ~-cell mass 
was expected to occur most quickly (8, 9, 11, 17). No significant difference in 
blood glucose levels was demonstrated between groups (5.3±0.3 vs. 4.9±0.2 
mmol/l). Moreover, plasma insulin levels of the INGAp104-118-treated animais at the 
end of the 10-day period were not significantly different from saline controls 
(3.3±0.5 vs. 4.3±0.7 ng/ml, p>O.05). 
2.3_2 f3-cell Mass Expansion of INGAp104-118_ Treated Normoglycaemic Hamsters 
The most striking feature of pancreases in INGAp104-118-treated animais 
was areas of neogenesis; small foci of islet-like cells budding from intralobular and 
terminal ductules (Figure 2_1). Over 90% of the putative new islet cells stained 
positive for insulin, while a sm ail minority stained positive for glucagon, 
somatostatin and pancreatic polypeptide. Examination of the mature islet 
population demonstrated a normal distribution of insulin-, glucagon-, and 
somatostatin-containing cells_ ln addition, sm ail ducts were identified with insulin-
positive cells in the epithelial wall (Figure 2.1 A), and sm ail extra-islet ~-cell 
clusters could also be identified in the tissue adjacent to the ducts, amongst the 
acinar cells (Figure 2.1 B). This process of neogenesis was much less apparent in 
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the tissue sections from the twenty saline-injected animais, ail of which were 
similar, with a lesser number of mature islets associated with ducts. 
To quantify the histological observation of new islet formation and to 
confirm the visual impression of increased neogenesis in INGAp104.118-treated 
animais, morphometric assessment of the islet cell mass was performed. In 
INGAp104-118-treated animais, the number of islets/mm2 of pancreatic tissue was 
64% greater than in control animais after 10 days (1.8±0.1 vs. 1.1 ±0.1; p<0.01), 
and 75% greater after 30 days of treatment (2.1 ±0.1 vs. 1.2±0.1; p<0.01) (Figure 
2.2A). Ten days after commencing INGAp104.118 administration, the median islet 
size in INGAp104-118-treated animais was 53% smaller compared to control animais 
(5200 vs. 11000 ~m2, p<0.05). This shift to smaller islets in INGAp104.118-treated 
animais, reflecting the induction of islet cell neogenesis with new islet formation, is 
shown in Figure 2.2B. 
To further characterize the increase in the amount of islet tissue induced by 
INGAp104.118, quantitative analysis of f3-cell mass was performed (Figure 2.3A). 
Using insulin stained tissue sections, it was determined that the insulin-positive 13-
cell mass was increased in INGAp104.118-treated animais by 44% at 10 days 
(3.7±0.5 vs. 2.6±0.4 mg; p<0.01) and by 31% at 30 days of treatment (4.6±0.4 vs. 
3.5±0.3 mg; p<0.025) when compared to aged-matched saline-treated animais. 
To correlate increased f3-cell mass and insulin content, we directly determined 
pancreatic tissue levels of insulin after 10 days of treatment with INGAp104.118 
(Figure 2.38). The pancreatic insulin content of INGAp104.118-injected animais was 
increased by 130% in comparison to saline-treated animais (33.5±1.9 vs. 14.6±0.8 
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~g/g, p<0.05). This observation further supports the data obtained by 
morphometric analysis. 
Analyses of f3-cell neogenesis were then performed to further characterize 
the increase in f3-cell mass. In comparison to control animais, INGAp104-118-treated 
animais exhibited a 3-fold increase in duct-associated f3-cell mass at 10 days 
(0.73±0.09 vs. 0.24±0_09 mg; p<0.05) and more th an a 2-fold increase following 
30 days (1.67±0.38 vs. 0.74±0.26 mg; p<0.05) (Figure 2.4A). Extra-islet acinar-
associated f3-cell mass was also significantly increased in INGAp104-118-treated 
animais by approximately 3-fold at both 10 and 30 days of treatment (d10: 48±8 
vs. 17±4 ~g; d30: 33±8 vs. 11±3 ~g; p<0.05) vs. saline injected controls (Figure 
4B). 
Having demonstrated the biological activity of INGAp104-118 on f3-cell mass 
expansion we sought to study the dose response between INGAp104-118 and f3-cell 
mass. f3-cell mass increased with escalating INGAp104-118 dose by 69%, 114%, 
and 122%, respectively for 50, 500 and 2500 ~ 9 (0.83±0.09, 1.40±0_25, 
1.78±0.37, 1.84±0.36 mg, respectively; Figure 2.5). 
2.3.3 Reversai of Diabetes After INGAp104-118 Treatment 
To investigate whether INGAp104-118 could reverse hyperglycaemia, diabetic 
C57BU6J mice were randomly allocated to treatment with INGAp104-118 (500 ~g 
per day i.p.), scrambled INGAP peptide (500 ~g per day i.p.), exendin-4 (4~g per 
day i.p.) or saline (equivalent volume) for a period of 39 days. 
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At the time of sacrifice, day 48, 4/4 of INGAp104-118-treated animais were 
normoglycaemic (8.1±1.2 mmol/I) (Figure 2.6). In contrast, ail animais in the other 
groups remained hyperglycemic (saline, 23.0±1.S; exendin-4, 27.1±2.6; scrambled 
INGAP, 27.2±1.9 mmol/I, p<O.OOS). 
The pancreatic tissue of INGAp104-118-treated animais contained foci of islet 
cell neogenesis and new islet formation (Figures 2.7A and B). We determined 
that 23.S±3.2% of pancreatic ducts in INGAp104-118-treated mice contained insulin-
positive cells versus 1 .O± 1.0% in control animais (p<0.001). Duct-associated J3-
cell mass in INGAp104-118-treated animais was 0.27±0.06 mg, compared to 
0.01 ±0.01 mg for control animais (p<0.001). Moreover, the number of islets per 
mm2 in INGAp104-118-treated mice was 1.9±0.S compared to 0.2±0.01 in the saline-
treated controls (p<0.01). INGAp104-118-treated animais also demonstrated an 
increase in PDX-1 immunoreactive duct cells compared to saline-treated mice 
(19.1±2.2% vs. 0.77±0.0%, p<0.01) (Figures 2.8A and B), and this was especially 
true in areas of islet cell neogenesis (Figure 2.8C). The majority of the cells in the 
newly formed islets were immunoreactive for insulin, with normal distribution of 
glucagon and somatostatin (Figures 2.9A and B). In contrast, in saline-treated 
animais, there was minimal neogenesis and the surviving islets showed evidence 
of extensive necrosis, along with Iymphocytic infiltration (Figure 2.7C). A 
photomicrograph of an islet from a normal untreated mouse is shown for 
comparison in Figure 2.7D. 
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Figure 2.1: Histological features of the pancreas following administration of 
INGAp104-118_ (A) j3-cell neogenesis (arrow) in the wall of a sm ail intralobular duct 
after 10 days of INGAp104-118 treatment. To the left is a normal islet. (8) An area 
of new islet formation outside its putative duct of origin (arrowheads) at 30 days_ 
The red stain identifies insulin protein visualized by immunocytochemistry. (bar = 
50 ~m) 
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Figure 2.2: Change in the islet population induced by INGAp104-118_ 
Normoglycaemic Syrian hamsters were treated with saline (D, n=10/time point) or 
INGAp104-118 (_, n=15/time point) for 10 or 30 days_ (A) Islet number (per mm2), 
and (B) bins of islet size distribution (11m2) as determined by computer-assisted 
morphometric analysis_ INGAp104-118-treated animais exhibited a significant 
increase in islet number. This was the result of new islet formation as reflected by 
the shift in the distribution of islet size to sm ail islets. * p<0.01, ** p<0.05 
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Figure 2.3: (A) ~-cell mass of Normal Syrian hamsters treated with saline (D, 
n=5, 6; for 10 and 30 days, respectively) or INGAp104-118 (-, n=5, 11) for either 10 
days or 30 days as determined by computer-assisted morphometric analysis. (B) 
Increase in pancreatic insulin content following 10 days of INGAp104-118 treatment 
* p<0_025, ** p<0.01. 
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Figure 2.4: Induction of ~-cell neogenesis by INGApl04-118. Normal Syrian 
hamsters were treated with saline (D, n=5ltime point) or INGApl04-118 (-, n=5/time 
point) for either 10 days or 30 days. (A) Duct-associated ~-cell mass, and (B) 
extra-islet acinar-associated ~-cell mass as determined using a computer-assisted 
morphometric system_ * p<0.05. 
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Figure 2.5: Increase in pancreatic endocrine cell mass with escalating INGAp104-
118 dose. Normal CD-1 mice treated with saline (D, n=10) or INGAp104-118 (_, 
n=10/group) at 50, 500 or 2500 !A-g/day for 31 days. f3-cell mass was determined 
using a computer-assisted morphometric system. * p<0.05 vs. saline. 
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Figure 2.6: Reduction in blood glucose by treatment with INGAp104-118. C57BU6J 
mice were rendered diabetic using a regimen of multiple injections of low-dose 
streptozotocin. The animais were then randomized to receive daily treatment with 
either saline (D, n=4) or 500 I-lg/day INGAp104-118 (-, n=4) for 39 days. * p<0.0001 
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Figure 2.7: Histological characteristics of the pancreas of streptozotocin-treated 
C57BL/6J mice with and without INGAp104-118 treatment (A) Pancreas of an 
INGAp104-118-treated animal showing an area of islet cell neogenesis, observed as 
endocrine-like cells budding from an adjacent intralobular ductule_ (8) A normal 
appearing islet in a pancreas of an animal treated with INGAp104-118_ (C) The 
pancreas of a saline-treated animal showing an islet with inflammatory cell 
infiltration characteristic of insulitis_ (0) The pancreas of a normal aged-matched 
non-treated control mouse showing the histological appearance of a normal islet 
for comparison_ (bar = 50 !lm) 
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Figure 2.8: Expression of PDX-1 and insulin in the pancreas of streptozotocin-
treated C57BL/6J mice administered either saline (0, n=4) or INGAp104-118 (-, 
n=4) for 39 days. (A) Photomicrograph of a PDX-1 stained pancreatic section 
from an INGAp104-118-treated animal, and (8) PDX-1 positivity quantified by 
computer-assisted morphometric analysis_ (C) Area of duct-associated islet 
neogenesis in an INGAp104-118-treated animal stained for both PDX-1 (brown) and 
insulin (red)_ (bar = 25 !lm) * p<O.01 
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B 
Figure 2.9: Immunocytochemistry of islet cell hormones in the pancreas of 
streptozotocin-treated diabetic C57BL/6J mice administered INGAp104-118. (A) An 
islet associated with a segment of duct epithelium (to the right) stained for insulin 
(black), and (B) for both glucagon and somatostatin demonstrating a normal 
presence and distribution of islet cell hormones. (bar = 30 !lm) 
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2.4 DISCUSSION 
We originally observed that duct-associated islet cell neogenesis, a 
hall mark of pancreatic organogenesis, occurred in response to partial pancreatic 
duct obstruction [85]. Subsequently, we reported that the crude tissue extract, 
ilotropin, prepared from the partially obstructed pancreas [155, 239], reversed 
hyperglycaemia in up to 60% of hamsters rendered diabetic with high dose STZ 
used to induce islet necrosis [156]. In this paper we now demonstrate that 
INGAp104.118 is capable of stimulating both duct and acinar-associated islet 
neogenesis, increasing f3-cell mass in a dose dependent manner and reversing 
STZ diabetes with insulitis in 100% of animais. We also show that the effects of 
INGAp104-118 are associated with induction of POX-1 expression, an important 
transcription factor involved in normal islet development [91]. It is evident from 
these experiments that the adult pancreas contains putative stem/progenitor cells 
that remain responsive to an appropriate stimulus for differentiation along an islet 
cell lineage and that INGAp104-118 can be this stimulus leading to reversai of a 
diabetic state. 
The greater response in the C57BU6J animais treated with INGAp104-118 in 
the present study compared to the previous results with the crude tissue extract 
[156] may be related to the higher dose of INGAp104-118 used on a molar basis 
and/or the lower doses of STZ required to create diabetes in mice. Thus, in 
comparison to hamsters, higher doses of STZ used in the earlier studies may 
have been toxic to the putative precursor cells destined for regeneration. We also 
cannot discard the possibility of greater efficiency of INGAp104-118 relative to native 
INGAP present in the crude ilotropin extract [158]. 
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The results obtained from normal hamsters in this study suggest that 
induction of an increase in new islet cell mass induced by INGAp104-118 reaches an 
asymptote and is not an unbridled growth. These results also suggest that the 
pancreas contains resident factors that exercise apparent homeostatic control of 
f3-cell expansion that serve as an effective brake against the development of islet 
cell tumors due to unbridled cell growth. Furthermore, in none of the INGAp104-118_ 
treated animais did we observe the development of hypoglycaemia due to the 
increased f3-cell mass. In fact, despite an elevation of pancreatic tissue levels of 
insu lin, circulating insulin concentrations were virtually identical to those seen in 
saline-treated controls. This indicates that a mature counter-regulatory 
mechanism, which was able to adjust the circulating level of insulin to the 
prevailing level of glucose, was functioning in INGAp104-118-treated animais. 
ln these studies, the histologic and morphometric evidence strongly 
supports the notion that the increase in f3-cell mass was due to islet cell 
neogenesis. INGAp104-118 administration, caused an increase in duct-associated 
f3-cell mass as weil as an increase in extra-islet acinar-associated f3-cell mass, 
both of which are indicative of f3-cell neogenesis [37, 88-90). This is in keeping 
with the report by Bouwens et al. who have suggested that single f3-cells or small 
clusters of f3-cells in the parenchyma of the pancreas are indicative of newly 
formed f3-cells [37]. Likewise, the observation of duct-associated f3-cells (or f3-cell 
clusters) suggests that these cells were derived trom duct-associated precursors 
by a process of neogenesis as weil [85, 88, 90, 152, 153). Importantly, these 
observations were extended and confirmed in the second part of this study in 
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which PDX-1 immunoreactivity was quantified. Thus, it was demonstrated that 
INGAp104.118 is capable of inducing ~-ce" neogenesis and new islet formation in 
STZ-diabetic animais in which the original adult islet population was destroyed. 
Furthermore, the reversai of STZ-induced diabetes, by INGAp104-118 
administration, indicates the target effect of INGAp104-118 on non-~-cells, 
supporting the notion of neogenesis. Moreover, the failure of a scrambled 
sequence of amino acids derived from INGAp104-118 to reverse hyperglycaemia 
highlights the specificity of the biological activity of INGAp104-118 with respect to 
induction of islet neogenesis and reversai of hyperglycaemia. 
Animais injected with exendin-4, a growth factor reported to stimulate islet 
neogenesis [161] failed to return to a normal glycaemic state. The failure of 
exendin-4 to reverse hyperglycaemia may be due to an insufficient dose for the 
specific animal model used here, even though this effect was reported in other 
types of animal models at similar doses [161, 242]. Ali of the previous work 
describing the glucose lowering and neogenic activity of exendin-4 has been 
performed in models of type-2 diabetes, and therefore the dose we used may not 
have been adequate to reverse hyperglycaemia in a model of type-1 diabetes 
where the ~-cell mass is markedly reduced. To date, the benefit of exendin-4 in 
models of type-1 diabetes remains an unresolved issue in the literature. In the 
only published report of the effects of exendin-4 in a multi-Iow dose STZ mouse 
model of type-1 diabetes, exendin-4 was injected before, during and after STZ 
administration, producing a modest reduction in blood glucose levels [243]. 
However, this experimental design is substantially different from the one we used 
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in our study, in which exendin-4 was only administered after hyperglycaemia was 
produced. 
The administered daily dose of 500 Ilg of INGAp104-118 may appear to be 
high, especially when compared to the administered dose of exendin-4, yet it has 
been shown that GLP-1 is most effective at doses between 100 and 1000 Ilg (23). 
Likewise, it should be noted that exendin-4 is actually the reptilian homologue of 
mammalian GLP-1 and has a potency more th an 5000-fold greater than an 
equimolar amount of the latter [161]. INGAp104-118 given intravenously or 
subcutaneously to CD-1 mice at 200 mg/kgobw produces plasma concentrations 
of about 1000 ng/ml at early time points (Iess th an 30 minutes) corresponding to 
666 nM knowing the molecular weight of INGAp104-118 is 1501.4. At times later 
th an 30 minutes, concentrations quickly decrease to less than 10 ng/ml (6.66 nM) 
(personal communication from J. Joly, Procter & Gambie). Assuming linear 
pharmacokinetics, the dose used in the current study (approximately 20 
mg/kgobw) would be expected to produce approximately 10-fold lower 
concentrations at similar times (i.e., resulting in a range from about 1 to 100 
ng/ml). These predicted concentrations are less than the concentration (250 
ng/ml, 167 nM) known to induce differentiation of human duct epithelial cells to 
islets in vitro [188]. GLP-1 was not used in our study because it has previously 
been shown to produce only transie nt reductions in blood glucose [244] due to its 
very short plasma half-life [245], necessitating a continuous intravenous infusion 
to obtain acceptable glycaemia in type 2 diabetic patients [244]. These data 
indicate that the administered dose of INGAp104.118 is appropriate. However, in the 
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future, INGAP analogs might have more potent biological actions, like exendin-4. 
To rule out a non-specifie effect on blood glucose of this dose of INGApl04-118, we 
administered an equimolar dose of a peptide synthesized from a scrambled 
sequence of the amino acids comprising INGApl04-118. This scrambled peptide 
had no demonstrable effect on blood glucose nor on the induction of islet cell 
neogenesis. 
A number of transcription factors are required to be expressed at 
appropriate times during the course of islet development in order to achieve the 
mature phenotype characteristic of pancreatic ~-cells [91]. Possibly the most 
significant of these is PDX-1 [91, 246]. In adult animais, the expression of PDX-1 
is repressed in the majority of pancreatic cells, with the exception of the ~- and a 
subset of ô-cells of the islets of Langerhans [247]. In this study the key 
observation has been made that INGApl04-118 is not only a pote nt inducer of islet 
cell differentiation, but that new islet formation appears to involve expression of 
PDX-1. Even more surprising was the extent to which ductal cells became 
positive for PDX-1 suggesting that many cells have the capacity to 
transdifferentiate. However, only a fraction of these cells developed into ~-cells 
suggesting that there are other determinants for progression to full hormonal 
secretory status. 
The observation of islet cel! neogenesis with new islet formation in this 
study is in keeping with previous reports [85] of potential islet cell progenitors in 
the adult pancreas that are capable of islet neogenesis following partial pancreatic 
duct obstruction. In this regard, it is of interest to note that a trial of partial 
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obstruction of the pancreas in a group of type-1 diabetic children was conducted 
over 70 years ago in New York by de Takats [65-68], who reported an "increase in 
sugar tolerance" following surgery. J)-cell neogenesis from pancreatic duct 
epithelial cells has also been found in other models of islet neogenesis [248] and 
raises the question of whether there is a futile attempt at new islet formation in 
patients with type-1 diabetes or that the newly formed islets are destroyed by 
ongoing immune-mediated mechanisms. The observation that an INGAP 
immunoreactive protein is found in the pancreases of patients with type-1 diabetes 
for 50-60 years [249] suggest that there may be factors that mitigate its biologic 
effects. It will be important to determine these factors to develop a complete 
understanding of the role of INGAP in islet neogenesis. 
The reversai of diabetes in C57BL/6J mice is ail the more pertinent to 
diabetes in humans. Considerable evidence implicates autoimmunity as a primary 
mechanism underlying J)-cell destruction in sorne forms of insulin dependent 
diabetes in humans [250]. Male mice of the C57BL/6J inbred strain are especially 
sensitive to the induction of insulin dependent diabetes by the J)-cell cytotoxin STZ 
and will produce J)-cell cytotoxic alloantiserum when immunized with islets [251]. 
When STZ is administered in a multi-Iow-dose regimen to male C57BL/6J mice, 
induction of hyperglycaemia is preceded by a mononuclear cell infiltrate in the 
pancreas [252, 253], as observed in our STZ-treated animais. The reversai of 
diabetes in this setting may be unique to INGAP, among the other members of the 
Reg/PSP family of proteins, which have been demonstrated to be associated with 
inflammation and autoimmune insulitis, but not to reverse diabetes [177, 180]. It 
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is of interest to speculate on why, in the presence of insulitis, the new islets were 
not destroyed as would be anticipated in human type-1 diabetes. There are at 
least three explanations for this. First, the newly differentiated cells may exhibit 
an antigenic profile that do es not predispose them to recognition and subsequent 
destruction in this model of diabetes. Secondly, the observed Iymphocytic 
infiltrate may not be as cytotoxic as that which characterizes the human disease. 
Thirdly, INGAp104-118 may exhibit immunomodulatory effects. 
Alternative animal models of type-1 diabetes include the NOD mouse and 
the BB rat, each of which has its own biological, and in particular immunological, 
idiosyncrasies [254]. We are currently working through many of these issues in 
the NOD mouse, including the prerequisite for immunosuppression, the need to 
deal with ongoing islet cell apoptosis, and the necessity for early trophic support of 
the newly forming islets. Our preliminary efforts suggest that it may indeed be 
possible to induce islet cell neogenesis using INGAp104-118 as part of a multi-
factorial approach (data not shown). 
Thus, the reversai of hyperglycaemia in an insulitis-like model of diabetes 
augurs particularly weil for the condition in humans. Although, INGAP was 
identified in the hamster pancreas, a human protein is recognized by an antiserum 
made to the hamster peptide. Moreover, this protein is highly expressed in the 
presence of islet neogenesis in the setting of partial obstruction in patients with 
chronic pancreatitis [249]. This novel ~-cell growth factor is likely to play a role in 
islet cell neogenesis in humans and INGAP is likely conserved between species 
[91 ]. 
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The induction of islet cell neogenesis by INGAp104-118 leading to new islet 
formation represents a potentially important approach for endogenous progenitor 
cell therapy. This approach has the potential to complement the use of fetal, 
allogeneic or xenogeneic tissue for transplantation of ~-cells into insulin-
dependent diabetic patients, and may be essential to in vitro expansion of putative 
stem/progenitor cells for subsequent transplantation. While this approach would 
have to be combined in sorne fashion with a tolerance induction strategy to 
prevent recurrence of insulitis in type-1 patients [255], this would not be necessary 
in patients with non-immune type-2 diabetes who could benefit from an 
augmentation of their native ~-cell mass. 
ln summary, we have demonstrated that a pentadecapeptide of native Islet 
Neogenesis Associated Protein (INGAP), a product of the pancreatic acinar cell, 
can induce in vivo islet cell differentiation from a putative progenitor cell(s) 
associated with the ductal epithelium, resulting in sufficient new islet formation to 
reverse a diabetic state. The ability of INGAp104-118 to promote fully functional and 
controlled islet cell differentiation and growth in vivo may provide a novel 
approach to the treatment of diabetes, and one that requires neither 
transplantation, nor the in vitro use of controlled differentiation of stem cells. 
Moreover, the demonstration that this effect can be achieved using a small 
peptide enhances its potential as a pharmacologic therapy. INGAp104-118 has 
recently successfully completed Phase 1/2a clinical trials. 
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BRIDGING STATEMENT BETWEEN MANUSCRIPTS 
The previous chapter demonstrated that INGAp104-118 therapy alone was 
sufficient to initiate islet neogenesis and result in quantifiable f3-cell mass 
expansion in hamsters and mice. It was also determined that f3-cell mass 
expansion increased in magnitude with the escalation of INGAp104-118 dose. 
Further to this work, INGAp104-118 administration to euglycaemic beagle dogs led to 
similar trends in f3-cell mass expansion (n=10/dose, p=0.22; Figure 2.10). When 
INGAp104-118 was administered to normoglycaemic cynomolgus monkeys there 
was no change in total f3-cell mass (n=8/dose, p=0.47; Figure 2.11) though there 
were indications of profound islet neogenesis (Figure 2.12). These results 
suggest that INGAp104-118 therapy could be effective across multiple species, 
including humans. Furthermore, when INGAp104-118 was administered to diabetic 
mice, it led to the reversai of their drug-induced hyperglycaemia. These findings, 
while promising, elicited the question as to whether the continuai stimulation of 
islet neogenesis via INGAp104-118 administration is a safe therapeutic approach 
that would not lead to unregulated f3-cell mass expansion and possible 
carcinogenesis. Therefore, the aim of Chapter 3 was to analyse the homeostatic 
mechanisms regulating induced f3-cell mass expansion. 
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Figure 2.10: Total pancreatic ~-cell mass in euglycaemic dogs with escalating 
INGAp104-118 dose. Beagle dogs treated with saline (D, n=10) or INGAp104-118 (., 
n=10/dose) at 0.5, 1.5 or 10 mg/kgobw/day for 34 days. ~-cell mass was 
determined using a computer-assisted morphometric system. p=0.22 
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Figure 2.11: Total pancreatic ~-cell mass in euglycaemic cynomolgus monkeys 
with escalating INGAp104-118 dose_ Cynomolgus monkeys treated with either saline 
(0, n=8) or INGAp104-118 (_, n=8/dose) at 10, 100 or 400 mg/kg-bw/day for 90 
days_ ~-cell mass was determined using a computer-assisted morphometric 
system. p=0.47 
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Figure 2.12: INGAp104-118 administration to cynomolgus monkeys lead to dramatic 
transformation of pancreatic tissue. (A) Photomicrograph of an insulin stained 
pancreatic section from a normoglycaemic male monkey administered INGAp104-
118 (400mg/kgobw/day) for 90 days. (B) Note the appearance of acinar metaplasia 
to duct-like structures and apparent islet neogenesis_ (bar = 125 /Am) 
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CHAPTER 3 
Documentation of Homeostatic Regulation of 
Induced ~-cell Mass Expansion 
Published as: 
Lipsett M, E Austin, M Castellarin, J Lemay, L Rosenberg. Evidence for the 
homeostatic regulation of induced j3-cell mass expansion. Diabetologia 
Dec;49(12): 2910-2919, 2006. 
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3.0 ABSTRACT 
Aims/hypothesis: Diabetes results from an insufficient insu lin secreting beta-cell 
mass. Restoration of beta-cell mass through pharmaceutically induced, 
endogenous beta-cell mass expansion may revolutionize diabetes therapy. 
However, it remains to be determined whether the induced beta-cell mass 
expansion is under homeostatic regulation. 
Materials and methods: Beta-cell mass expansion rates were derived from three 
separate studies of continuous stimulation of islet neogenesis, including the partial 
duct obstruction (PDO) of euglycaemic Syrian hamsters, administration of the 
beta-cell neogenic agent INGAp104-118 to euglycaemic Syrian hamsters, as weil as 
to euglycaemic CD-1 mice. Incidence of islet neogenesis, average beta-cell size, 
as weil as beta-cell replication and apoptotic rates were determined. 
Results: PDO led to a .... 2.5-fold increase in endocrine tissue following 56 days 
(p<0.05). From day 0-to-7 the average rate of change of islet area was 
12.7%/day, which then decreased to 5.3%/day from day 7-to-42 and further 
decreased to 2.8%/day from day 42-to-56. INGAp104-118 administration to adult 
hamsters led to a 31 % increase in total beta-cell mass at 30 days (p=0.031). 
From day 0-to-10 the average rate of beta-cell mass expansion was 148 Ilg/day, 
whereas from day 10-to-30 it decreased to 45 Ilg/day. INGAp104-118 administration 
to adult CD-1 mice resulted in a .... 2-fold increase in beta-cell mass following 31 
days (p=0.021), however after 90 days there was no significant difference versus 
age-matched controls (p=0.30), though the neogenic beta-cell mass was ~-fold 
greater (p=0.026). Beta-cell replication was decreased by 56% (p<0.048), 
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whereas beta-cell apoptosis was 4-fold greater (p<O.003) in 90-day INGAp104-118_ 
treated mice compared to age-matched controls. 
Conclusions/interpretation: These data indicate that in the presence of ongoing 
islet neogenesis, homeostatic regulatory mechanisms intervene to match beta-cell 
mass to the prevailing metabolic requirements. 
Page 102 
3.1 INTRODUCTION 
Diabetes, whether type 1 or type 2, is arguably a disease ultimately 
caused by a loss of j3-cell mass [7, 11, 12]. Over the last decade it has been 
recognized that tight glycaemic control can prevent diabetes-associated 
complications [62, 63, 256]. To date, the only means of achieving such stringent 
control has been the restoration of j3-cell mass through pancreas or islet 
transplantation, which results in near perfect control of blood glucose levels 
without hypoglycaemic episodes that are associated with intensive insulin therapy 
[69, 70]. Pancreas transplantation is currently far more successful in maintaining 
long-term reversai of hyperglycaemia than islet transplantation, which is still an 
emerging technology [64, 71, 72]. However, both approaches are limited by the 
shortage of available organs and the need for chronic immunosuppression. Thus, 
novel strategies need to be developed that increase the insulin-producing j3-cell 
mass. 
An innovative alternative to islet replacement by transplantation is the 
induction of islet cell neogenesis, i.e. the growth of new insulin-producing cells 
from non-insulin-producing progenitors. This approach is appealing since the 
need for organ donation would be removed as a limiting factor. Moreover, the 
pharmacological induction of islet neogenesis has been confirmed to lead to j3-cell 
mass expansion and reversai of hyperglycaemic states in various animal models 
[137,139, 171,201]. However, it is possible that the stimulation of cell 
differentiation and expansion could potentially lead to unrestricted growth and 
hyperfunction that is characteristic of neoplasia [128]. For example, unbridled islet 
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neogenesis, termed nesidioblastosis, was initially reported in 1938 [257]. Similar 
cellular mechanisms associated with islet neogenesis, including phenotypic 
dedifferentiation and increased cellular proliferation, are implicit in the 
transformation of cells to a cancerous state [128]. Moreover, growth factors used 
to stimulate islet neogenesis have also been associated with various cancers 
[128, 178, 205, 206]. It is therefore of utmost importance to determine if 
pharmaceutically induced ~-cell mass expansion remains under homeostatic 
control. 
Previous work do es indeed suggest that the ~-cell mass is responsive to 
changing metabolic demands. In the pregnant rat the ~-cell mass initially expands 
and then involutes following parturition, closely matching ~-cell mass to the 
prevailing metabolic demands [227, 228]. This regulation of j)-cell mass may also 
be operative in humans, as increased islet neogenesis and j)-cell mass expansion 
in the presence of obesity have been reported [12]. Comparable cell mass 
regulation has also been observed in lacrimal glands and breast tissue [229-235]. 
Accordingly, we hypothesise that in the setting of continuai induction of 
islet neogenesis, homeostatic cellular mechanisms regulate j)-cell mass to meet 
the prevailing functional needs. In order to test this hypothesis a new analysis of 
j)-cell mass expansion dynamics was performed using data from two previously 
reported studies [85, 139]. To acquire additional corroborating data, an analysis 
of chronic pharmacological stimulation of islet cell neogenesis in a third study was 
performed in which total j)-cell mass, neogenic j)-cell mass, average ~-cell size, 
replication and apoptosis were determined. 
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3.2 MATE RIALS AND METHODS 
Data from three separate animal studies are reported: (1) partial duct 
obstruction (POO) of euglycaemic adult hamsters [85]; (2) administration of a 
pentadecapeptide with the same amino acid sequence as residues 104-118 of 
islet neogenesis-associated protein (INGAp104-118) to euglycaemic hamsters [139]; 
and (3) administration of INGAp104-118 to euglycaemic mice_ Ali animal studies 
were performed in accordance with Canadian Council of Animal Care and McGiII 
University guidelines. 
3.2. 1 Animal Models 
3.2.1.1 Partial Duct Obstruction 
Experiment 1, first described in 1983, involved the partial duct obstruction 
of adult female Syrian hamsters (Charles River Breeding Laboratories, Syracuse, 
NY; n=24) by performing a midline laporotomy and wrapping the head of the 
pancreas with a 2 mm wide piece of cellophane tape or sham operation [85]. 
After 7, 42 and 56 days hamsters were anesthetized with sodium pentobarbital, 
and a thoracotomy performed. Tissues were perfused with a solution of 1 % 
gluteraldehyde and 4% formaldehyde and the pancreas was then removed and 
post-fixed in 10% formalin and processed for immunohistochemical analysis. 
3.2.1.2 Administration of INGAp104-118 to Euglycaemic Hamsters 
Experiment 2, first described in 2004, involved administration of INGAp104-
118 (a Reg family member) to 8 week old female Syrian hamsters (Charles River 
Breeding Laboratories, St Constant, QC, Canada; 250 I-1g twice daily; n=30) or an 
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equivalent volume of saline (n=20) [139]. After 10 and 30 days hamsters were 
anesthetized with sodium-pentobarbitol (40 mg/kg body wt, Lp.) and killed by 
exsanguination. The pancreas was removed, blotted on tissue paper, weighed, 
fixed in 10% formalin and processed for immunohistochemical analysis. 
3.2.1.3 Administration of INGAp104.118 to Euglycaemic Mice 
Experiment 3 involved the administration of INGAp104.118 to 6-8 week old 
CD-1 mice (Charles River, MA, USA) for 31 days (0, 50, 500, or 2500 ~g once 
daily, Lm.; n=40) or for 90 days (0, 1000, 2500 or 5000 ~g once daily, s.c.; n=78). 
Animais were killed by cervical dislocation, the pancreas excised, blotted, 
weighed, fixed in 10% formalin and processed for routine immunohistochemistry. 
3.2.2 Immunohistochemistry 
Pancreatic sections, 4-5 ~ m thick, were de-waxed in xylene and 
endogenous peroxidase activity was blocked using a 3% solution of hydrogen 
peroxide in methanol (for sections to be stained with 3,3'-diaminobenzidine 
tetrahydrochloride (DAB, Sigma-Aldrich Canada, Oakville, ON, Canada)). 
Sections were th en washed in PBS and incubated with blocking buffer (Zymed 
Laboratories, San Francisco, CA, USA) for 15 minutes at room temperature. 
Slides were stained with one or more primary antibodies, including insulin (guinea 
pig anti-porcine, 1 :1000; Dako Diagnostics Canada, Mississauga, ON, Canada); 
proliferating cell nuclear antigen (PCNA) (mouse anti-rat, clone PC10, 1:100; 
Dako Diagnostics Canada) and TUNEL detection kit (Roche, Laval, QC, Canada). 
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Siides stained for PCNA and TUNEL were incubated with 0.1 M citrate buffer for 9 
minutes at 90°C for antigen retrieval before primary antibody application. Siides 
were incubated with primary antibodies overnight at 4°C before being washed in 
PBS and incubated with the secondary antibodies for 20 minutes (Histostain Plus 
Kit, Zymed Laboratories, San Francisco, CA, USA) or 1 hour (rhodamine-
conjugated anti-guinea 1 :200; Jackson ImmunoResearch Laboratories, West 
Grove, PA, USA) at room temperature. After washing in PBS immunofluorescent 
sections were cover-slipped using Vectashield (Vector Laboratories, Burlingame, 
CA, USA) and light sections were incubated with either horseradish peroxidase or 
alkaline phosphatase conjugate (Histostain Plus Kit) for 20 minutes, and 
developed using DAB or New Fuchsin (Dako), respectively. Ali light 
immunohistochemical si ides were counterstained with Harris' haematoxylin 
(Sigma-Aldrich) and cover slipped using Permount (Fisher Scientific, Ottawa, ON, 
Canada). 
3.2.3 f3-cell Mass Determination 
Percentage ~-cell area was determined through analyses of insulin-stained 
sections as previously described [87, 89]. Histological sections were analysed 
using an Olympus BX60 microscope and Image-Pro Plus software, version 4·0 
(Olympus Canada, Markham, ON, Canada; experiments 1 and 2), or using a 
Zeiss Axioskop 40 microscope and Northern Eclipse software, version 6·0 (Empix 
Imaging, Mississauga, ON, Canada; experiment 3). Islets from insulin-stained 
sections were identified, traced and thresholded using the software system to 
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determine stained tissue area. The total pancreatic tissue area was also 
measured and the percent ~-ce" area calculated. This percentage was then 
multiplied by the weight of the excised organ to derive the ~-cell mass. 
Classification of neogenic ~-cell mass was performed as previously 
described [37, 87, 89, 137]. Duct-associated neogenic ~-cell structures were 
categorized as sm ail «500 ~m2, as determined by the image analysis system) 
insu lin-positive clusters associated with the ductal epithelium (Figure 3.1 A). 
Acinar-associated neogenic ~-cell structures were categorized as small «500 
~m2) acinar-associated structures devoid of any other juxtaposed endocrine cells 
(Figure 3.1 B). Focal areas of neogenesis were categorized as structures 
characterized by disorganized insulin-positive staining with apparent infiltration of 
duct-associated cells (Figures. 3.1 C and 0). 
For the analysis of hamster pancreases with partially duct obstruction 
(experiment 1), percentage islet area was used as a surrogate for ~-cell mass. 
Briefly, the number of islets per mm2 of pancreatic tissue and the average islet 
size were determined by manually tracing a minimum of 100 islets per animal. 
Total islet area was then determined by multiplying the average islet size by the 
number per mm2. 
3.2.4 Determination of f3-cell Size, Replication and Apoptosis 
Average ~-cell size, replication and apoptotic indices were determined for 
mice administered saline or INGApl04.118 for 31 or 90 days (2500 ~g/day) in 
experiment 3. The total number of ~-cell nuclei and the number of PC NA-positive 
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~-cell nuclei and TUNEL-positive ~-cell nuclei were determined using the Northern 
Eclipse image analysis system (Empix Imaging). Average ~-cell size was then 
determined as total insulin area divided by total number of ~-cell nuclei for each 
animal. ~-cell replication indices were determined as the number of ~-cell PCNA-
positive nuclei divided by total number of ~-cell nuclei (average number of nuclei 
counted/animal: 3670±411; n=5 INGAp104.118, n=4 saline for each time point). 
Apoptotic indices were determined as total number of TUNEL-positive nuclei 
divided by total number of ~-cell nuclei for each animal (average number of nuclei 
counted/animal: 2858±340; n=5 for each time and treatment). 
3.2.5 fJ-cell Mass Dynamics 
The average daily rate of change of islet area (experiment 1) or ~-cell mass 
(experiment 2) was determined by subtracting the initial value from the islet area 
of the next time point and dividing by the number of days between time points. 
Curves predicting islet or ~-cell mass expansion dynamics were derived from islet 
area or ~-cell mass from each treatment group, expressed as a percentage of 
age-matched control animais (Fig. 7). The ~-cell mass dynamics curve for 
experiment 3 was constructed using the ~-cell mass from mice in the 2500 !lg/day 
group. 
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3.2.6 Statistical Analyses 
Ali values are reported ± standard error of measurement. Student's t-test 
or one-way ANOVA were performed where appropriate. Results with a p value of 
< 0.05 were considered significant. 
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3.3 RESULTS 
Following partial duct obstruction, average islet size initially decreased (day 
7) before increasing thereafter by ....... 25% (day 56, p<0.05; Figure 3.2A). Islet 
density (the number of islets per mm2), however, was consistently double that of 
control animais (p<0.05; Figure 3.28), resulting in an approximately 2.5-fold 
increase in islet area by day 56 (p<0.05; Figure 3.2C). From day 0 to 7, the 
average daily rate of change of percent islet area (d(% islet area)/d~ay) was 
determined to be 12.7%/day. This rate then declined to 5.3%/day from day 7 to 
42 and again to 2.8%/day from day 42 to 56 (Figure 3.20). 
Administration of INGAp104-118 to euglycaemic hamsters induced a 2.5-fold 
increase in total duct-associated J3-cell mass (p=0.004; Figure 3.3A) and an 
approximate 3-fold increase in acinar-associated neogenic J3-cell mass (p<0.001; 
Figure 3.38) [139J. Total J3-cell mass increased by 44% at day 10 and 31% at day 
30 in comparison to saline controls (p=0.031; Figure 3.3C) [139]. This increase of 
44% corresponds to an initial J3-cell mass expansion rate of 148 !lg/day (from day 
o to day 10). The average rate of expansion then decreased to 45 !lg/day (day 10 
to 30; Figure 3.30) representing a reduction in the rate of J3-cell mass expansion 
of ....... 70% .. 
Following the administration of INGAp104-118 to euglycaemic CO-1 mice 
induced, a dose-dependent increase in total J3-cell mass at 31 days (mean total 
mass: 0.83±0.09, 1.40±0.25, 1.78±0.37, 1.84±0.36 mg for 0, 50, 500, 2500 
!lg/day, respectively; p=0.021; Figure 3.4A). At 90 days of treatment there was no 
difference in total J3-cell mass between any of the groups (1.87±O.15, 1.55±0.12, 
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1.88±0.13, 1.69±0.18 mg for 0, 1000, 2500, 5000 (-tg/day, respectively; p=0.30; 
Figure 3.4B). The observation that the ~-cell mass was not different from control 
animais at 90-days, despite the persistence of a neogenic stimulus, led us to 
investigate the potential mechanisms of ~-cell mass expansion and involution in 
the CD-1 mice. 
To investigate whether the degree of ~-cell neogenesis differed between 
control mice (saline) and those administered INGAp104.118 for 90 days, neogenic 
structures were quantified from insulin stained slides. In INGAp104-118-treated 
mice, the number of small duct-associated neogenic structures doubled (p=0.029; 
Figures 3.1 A and 3.4C) and the number of focal areas of neogenesis increased 
approximately 4-fold (p=0.008; Figures 3.1C, D and 3.4D) versus age-matched 
control mice. The neogenic ~-cell mass increased ,..",4-fold in INGAp104-118-treated 
mice compared with that in control mice (p=0.026; Figure 3.5A). This result, 
together with the observation that total ~-cell mass of the INGAp104-118-treated 
mice did not differ from control animais (p=0.30; Figure 3.5B) suggests that there 
is a corresponding increase in ~-cell loss to maintain the ~-cell mass at control 
levels (Figure 3.5C). 
ln order to determine if ~-cell atrophy, decreased replication or apoptosis 
could account for this proposed ~-cell loss, analyses of average ~-cell size, 
replication rate and apoptotic index of 31-day and 90-day control and INGAp104-118_ 
treated mice were performed. There were no significant difference in average ~­
cell size (119.1±5.7 vs. 128.4±3.9 (-tm2 p=0.18; Figure 3.6A) or replication 
(0.66±0.12 vs. 0.67±0.16% p=0.94; Figures 3.6B and D) in control versus 
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INGAp104-118-treated mice after 31 days, respectively. However, following 90 days 
of INGAp104-118 treatment there was a significant increase in average ~-cell size 
(119.6±2.5 vs. 141.9±1.2 ~m2, Figure 3.6A; p<0.001). Conversely, there was a 
concomitant decrease of ,...,50% in the ~-cell replication index of INGAp104-118_ 
treated mice (0.79±0.17 vs. 0.35±0.05 %; p=0.048; Figure 3.68). When ~-cell 
apoptosis was analysed at 31 days by TUNEL, no significant difference was 
observed between the control and INGAp104-118-treated mice (0.132±0.027 vs. 
0.091±0.035 %, p=0.33, respectively, Figures 3.6C and E). In contrast, following 
90 days of treatment there was an approximate 4-fold increase in TUNEL-positive 
~-cells in INGAp104-118-treated mice (0.079±0.021 vs. 0.313±0.016 %; p=0.003; 
Figure 3.6C). 
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Figure 3.1: Insulin stained sections (brown) from CD-1 mice administered 
INGAp104-118 (2500 !-lg/day) for 90 days illustrating small, extra-islet duct-
associated p-cell clusters (A), an extra-islet acinar-associated single p-cell (8), 
and duct-associated focal areas of neogenesis (C, D)_ (bar = 50 !-lm) 
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Figure 3.2: Average islet size (A), islet density (8) and insulin area (percent of 
total tissue) (C) of hamsters following sham surgery (0, n=6 per time point) or 
partial duct obstruction (., n=6 per time point). (0) Daily rate of change of insulin 
area in hamsters with partial duct obstruction (n=6 per time point). *p<O.05 versus 
sham control hamsters. 
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,,-.. 
Figure 3.3: (A) Total duct-associated ~-cell mass in hamsters administered saline 
(D, n=5 per time point) or INGAp104-118 (-, n=5 per time point) for 10 or 30 days; 
(8) extra-islet acinar-associated neogenic ~-cell mass; (C) total ~-cell mass; (0) 
daily rate of change of ~-cell mass in INGAp104-118-treated hamsters (n=5 per time 
point). *p<0.05 versus saline control mice. 
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Figure 3.4: (A) ~-cell mass in CD-1 mice administered saline or INGAp104-118 at 
various doses for 31 days (n=10 per group); (8) ~-cell mass in mice administered 
saline or INGAp104-118 for 90 days (n=20 per group, except for the 5000 ~g/day 
group, where n=18); (C) density of sm ail duct-associated insulin-positive clusters 
in 90-day treated animais (n=8 per group); (D) density of focal areas of 
neogenesis in 90-day treated animais (n=8 per group)_ *p<0_05 vs. saline control 
mice. 
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Figure 3.5: (A) Total neogenic j3-cell mass from 90-day saline and INGAp104-118_ 
treated mice (n=8 per group); (B) total j3-cell mass in 90-day saline and INGAp104-
118-treated mice; (C) predicted net j3-cell loss in 90-day INGAp104-118-treated mice, 
derived from values in (A) and (B)_ *p<O.05 versus saline control mice. 
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Figure 3.6: (A) Average f3-cell size in 31- and 90-day saline (D, n=4 per time 
point) and INGAp104-118-treated mice (., n=5 per time point); (8) percentage of 
total f3-cell nuclei positive for PCNA in CD-1 mice treated with saline (n=4 per time 
point) or INGAp104-118 for 31 or 90 days (n=5 per time point); (C) percentage of 
total j3-cell nuclei positive for TUNEL in CD-1 mice treated with either saline or 
INGAp104-118 for 31 or 90 days (n=5 for each group and time point). (0) 
Representative photomicrograph of an insulin and PCNA double-stained 
pancreatic section from an INGAp104-118-treated mouse. (E) Representative 
photomicrograph of a TUNEL-stained pancreatic section from an INGAp104-118_ 
treated mouse. *p<0.05 versus saline control mice. (bar = 50 !-lm) 
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Figure 3.7: (A) Predicted ~-cell mass expansion curves based on data from 
partial duct obstructed hamsters; (8) hamsters administered 500 ~g/day INGAp104-
118 for up to 30 days; (C) CD-1 mice administered INGAp104-118 (2500 ~g/day) for 
up to 90 days_ Ali values represent the percent change from age-matched 
controls for islet size (~m2) - islet density (#/mm2) (A) or total ~-cell mass (8) and 
(C). 
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3.4 DISCUSSION 
There is accumulating evidence from different animal models suggesting 
that pancreatic ~-cell mass is dynamic and changes to accommodate the body's 
needs [79, 89,226-228, 258, 259]. Here we report that regulatory mechanisms do 
indeed appear to be operative in the regulation of the insulin-producing ~-cell 
mass, even in the setting of continuai stimulation of islet neogenesis. Moreover, 
the data reported herein suggests that this regulation occurs through decreased ~­
cell replication and increased ~-cell apoptosis. 
Although the three studies of induced islet expansion analysed in this 
report were somewhat different in design, they ail shared an initial increase in ~­
cell mass followed by an involution of this expanded ~-cell mass towards age-
matched control levels (Figure 3.7). This expansion and subsequent involution is 
similar to that observed during pregnancy and post-partum periods in rodents 
[227, 228]. During pregnancy the ~-cell mass of the gravid female almost doubles 
in response to the increased metabolic demands and altered hormonal milieu 
[227, 228]. However shortly after birth, when the hormonal environment and 
metabolic demands revert to the non-pregnant state, the expanded ~-cell mass 
involutes, returning to normal levels through ~-cell atrophy, increased f3-cell 
apoptosis and decreased f3-cell replication [228]. This mirrors quite closely what 
we have observed in the setting of continuai stimulation of islet neogenesis. 
The dynamic and highly complex nature of these homeostatic mechanisms 
is highlighted by the increase in average f3-cell size in those animais treated with 
the Reg3 member INGAp104.118 for 90 days. This is perhaps somewhat 
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counterintuitive, since ~-cell hypertrophy would contribute to an expansion of the 
~-cell mass, not involution, as was seen in 90-day treated mice. However, this 
finding must be viewed in the context of an approximate 50% reduction in ~-cell 
replication concomitant with a 4-fold increase in apoptotic ~-cell death. This 
observation of ~-cell hypertrophy following 90-day INGAp104-118 stimulation is in 
agreement with what has previously been reported in isolated rodent islets [179]. 
Interestingly, the over-expression or administration of Reg1 has been shown to 
lead to an increase in ~-cell mass through an increase in ~-cell replication, 
although ~-cell size was not assessed in these studies [175, 182, 260, 261]. The 
increase in ~-cell replication following Reg1 administration contrasts with our 
study as we observed that ~-cell mass more than doubled following 31 days of 
treatment in mice, without a concomitant increase in average ~-cell size, PCNA 
labelling of ~-cells, or a decrease in TUNEL-positive ~-cells. This suggests that 
the increase in ~-cell mass cornes from an increase in islet neogenesis. Thus, 
INGAp104-118 may lead to ~-cell mass expansion through a different mechanism 
than the other Reg family members. 
Even though enhanced ~-cell apoptosis and decreased ~-cell proliferation 
appear to be responsible for the involution of the expanded ~-cell mass, the 
underlying stimulus prompting involution is not readily apparent. The fact that 
plasma glucose and insulin levels in the saline and INGAp104-118-treated hamsters 
are not significantly different would suggest that other factors are responsible for 
triggering the process of involution [139]. 
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f3-cell involution can result from removal of a f3-cell growth/survival factor, 
the direct stimulation of f3-cell death, or both. For example, administration of 
gastrin is associated with f3-cell growth and decreased f3-cell apoptosis in the 
setting of pancreatic regeneration [137]. This suggests that removal of gastrin-
stimulated growth could aid in the involution of f3-cell mass. Furthermore, gastrin 
has been shown to regulate the expression of pancreatic Reg genes, suggesting 
another means of f3-cell cell mass regulation [262]. On the other hand, elevated 
levels of cytokines, specifically, IL-1f3, TNF-a and IFN-y, are directly linked to 
increased f3-cell apoptosis levels [263]. Thus, it is possible that decreased levels 
of growth factors, as weil as increased levels of cytokines could be responsible for 
initiating the involution of the expanded f3-cell mass in our models. We are 
currently furthering our understanding of the control of endogenous Reg protein 
and, more specifically, INGAP expression, which may also play a role in these 
models [264]. 
Recent information supports the effectiveness of islet neogenesis therapy 
to reduce HbA1C values [265]. The finding that continuai stimulation of islet cell 
neogenesis does not result in unbridled f3-cell mass expansion, suggests that 
induction of islet neogenesis would be a safe therapy for individuals with diabetes. 
However, there may still be some issues to resolve. For example, islet 
neogenesis can occur through one of three pathways: stem cell activation, direct 
transdifferentiation of mature cell phenotypes or indirect transdifferentiation of 
mature cell phenotypes. The direct transdifferentiation pathway is simply the 
differentiation of a mature cell into an insulin-producing cell without the cell going 
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through a primordial stage, and is suggested by the morphological observation of 
extra-islet duct- and acinar-associated single ~-cells [37, 89, 139]. Indirect 
transdifferentiation involves the dedifferentiation of previously terminally 
differentiated cells into a more primitive cell phenotype followed by 
redifferentiation into a mature ~-cell [89, 135-137]. This metaplastic 
transformation of acinar tissue, leading to the induction of so-called tubular 
complexes, has been observed in many different models of pancreas regeneration 
and islet expansion [89, 136,137, 169, 171,205]. The significance of these duct-
like structures with respect to carcinogenesis remains to be fully explored. 
Metaplastic transformation of acinar tissue has not been observed in any of the 
rodent studies of INGAp104-118 administration. 
Even though the induction of ~-cell mass expansion does occur in a 
regulated manner, there still remains the question as to whether or not 
pharmaceutical expansion of the insulin-producing cell mass will prove effective in 
ameliorating both types of this disease. Results from clinical Phase 2a proof of 
principle trials suggest that new ~-cells can be formed in the setting of both type 1 
and type 2 diabetes [265]. It still remains to be determined whether, and to what 
extent, these newly formed ~-cells are protected from the autoimmune insulitis 
that characterizes type 1 diabetes [266). 
ln conclusion, continuai stimulation of islet neogenesis does not lead to 
unregulated cell expansion. Heightened ~-cell apoptosis and diminished ~-cell 
replication serve to regulate induced ~-cell mass expansion to meet the body's 
prevailing needs. This therapeutic approach seems to currently have the greatest 
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potential in the setting of type 2 diabetes, although with advances in 
immunosuppression, it could be justifiably applied in the setting of type 1 diabetes. 
Page 132 
3.5 ACKNOWLEDGEMENTS 
M.L. is supported by a fellowship from the CIHR (Canadian Institutes for 
Health Research) and the Diabetic Children's Foundation of Montreal. L.R. is a 
Chercheur National (national scientist) of the Fonds de la Recherche Scientifique 
Ouebec (FRSO). The authors would like to thank the Montreal Chapter of the 
Lion's Club for their support, Rennian Wang for her work with INGAp104-118-treated 
hamsters, Minh Duong and Nora Malek for their technical aid and Reid Aikin for 
helping with this manuscript. 
Page 133 
BRIDGING STATEMENT BETWEEN MANUSCRIPTS 
ln Chapter 3 it is observed that continuai stimulation of islet neogenesis via 
INGAp104-118 administration does not lead to unbridled j3-cell proliferation. Induced 
j3-cell mass expansion is regulated through inhibition of j3-cell replication as weil 
as through an augmentation of j3-cell apoptosis. The observation that homeostatic 
mechanisms remain active to match the resultant j3-cell mass with the body's 
needs indicates that INGAp104-118 may indeed be safe to administer as a human 
therapy. The next step is to determine if INGAp104-118 therapy will be effective in 
stimulating islet neogenesis in humans, leading to an expanded j3-cell mass. 
Thus, the aim of Chapter 4 was to determine the efficacy of INGAp104-118 in 
stimulating islet neogenesis trom non-endocrine human pancreatic tissue. 
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CHAPTER 4 
Documentation of Morphological Plasticity and Neogenic 
Potential of Adult Human Acinar Tissue 
Published as: 
Lipsett M, M Castellarin, L Rosenberg. Acinar Plasticity: Development of a novel 
in vitro model to study human acinar-to-duct-to-islet differentiation. 
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Page 135 
Doctoral Candidate's Contribution - Manuscript 3 
The doctoral candidate performed ail human tissue collection, experimental 
and immunohistochemical procedures, data collection and analysis, statistical 
analyses and manuscript writing. Other co-authors contributed in manuscript 
preparation and technical expertise in pancreatic digestions. 
Page 136 
4.0 ABSTRACT 
Objectives: The plasticity of pancreatic tissue is demonstrated in many pancreatic 
diseases. It has previously been shown that pancreatic islet-to-duct 
transformation and acinoductal metaplasia have been associated with both 
pancreatic regeneration and adenocarcinoma in various in vivo and in vitro 
settings. Understanding this inherent morphogenetic plasticity of the adult 
pancreas could lead to new therapeutic approaches to pancreatic disease. 
Methods: Cadaveric human pancreases (n=7) were digested and purified acinar 
tissue, which was ...... 85% immunoreactive for amylase and .... 15% CK19 
immunoreactive, was embedded in a type-1 collagen matrix and cultured in a 
differentiation medium (DM) consisting of DMEM/F12 medium supplemented with 
cholera toxin (CT, 100 ng/ml), EGF (10 ng/ml) and insulin (24 mU/mi) for 8 days. 
Following this initial period, the resulting tissues were cultured in DM without CT, 
supplemented with gastrin (50 nM) and HGF (10 ng/ml), with INGAp104-118 (167 
nM) or with gastrin + HGF + INGAp104-118 for 6 days. Tissue samples were then 
analysed for amylase, cytokeratin 19, PDX-1, and endocrine hormone 
immunoreactivity as weil as dithizione positivity. 
Results: Following 8 days of culture, .... 90% of acini transformed into duct-like 
structures (DLS). This acinoductal transformation was characterized by a 
complete absence of amylase staining, with virtually ail cells CK19 
immunoreactive. Addition of INGAp104-118 led to an .... 18-fold increase in PDX-1 
immunoreactivity, though without an observed increase in insulin production as 
measured by dithizone positivity. However, when acinar-derived DLS were 
cultured with gastrin + HGF + INGAp104-118 the total incidence of dithizone positive 
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structures increased -6-fold (10.9±2.9 vs. 1.7±O.4%; p=O.037). Treatment with 
gastrin + HG F alone led to no significant change in any of the measured 
parameters. 
Conclusions: We have developed a novel in vitro model of adult human 
acinoductal metaplasia that will aid, not only in developing new methods of 
expanding ~-cell mass, but also provide insights into pancreatic carcinogenesis. 
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4.1 INTRODUCTION 
Recently, the potential of adult pancreatic acinar tissue to transform into 
various cell types has been demonstrated [89, 115, 128, 129, 136, 137]. Direct 
transformation of adult rodent acini into insulin-containing tissues, as weil as 
indirect acinar-to-islet transformation identified as acinar-to-duct transformation 
(acinoductal metaplasia) followed by subsequent duct-to-endocrine 
redifferentiation, can both le ad to an expanded (3-cell mass. Acinoductal 
metaplasia, which is observed in numerous in vivo settings in association with 
pancreatic regeneration and (3-cell mass expansion, occurs through acinar-to-duct 
transdifferentiation [115, 129]. These metaplastic structures, commonly referred 
to as tubular complexes, appear to contain enhanced islet neogenic potential [89, 
136, 137, 163, 170]. These findings, together with the fact that acinar tissue 
makes up approximately 80% of the adult pancreas, suggests that therapies 
directed at enhancing acinar-derived (3-cell mass expansion could be very 
successful at augmenting the (3 -cell mass and ameliorating diabetic 
hyperglycaemia. 
Islet neogenesis from pancreatic tubular complexes is thought to occur 
under the influence of epidermal growth factor (EGF), gastrin, HGF and likely 
many other growth factors [137, 160, 163, 172, 267J. Since these cytokines have 
demonstrated efficacy in animal models of islet expansion, it is suggested that 
they may also have potential to increase human (3-cell mass. For example, 
combination therapy with EGF and gastrin has been observed to increase the 
insulin content of human pancreatic islet preparations cultured for up to 28 days, 
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presumably through the differentiation of duct cells present in the semi-purified 
islet culture [203]. 
ln addition to EGF and gastrin, Reg family members are also upregulated in 
settings of pancreatic regeneration [158, 162, 175, 180-182, 187, 188, 190]. Islet 
Neogenesis Associated Protein (INGAP), a hamster Reg3 protein, has been 
shown to stimulate duct-to-islet neogenesis leading to ~-cell mass expansion and 
reversai of diabetic hyperglycaemia in a mouse model, as weil as increase acinar-
to-islet differentiation in Syrian hamsters [139]. 
Strategies to increase ~-cell mass are recognized as being increasingly 
important. The reason for this lies in the ongoing limitations related to widespread 
application of human islet transplantation as a means to restore normoglycaemia 
in type 1 diabetic recipients. Donated organs remain a very scare resource and to 
date, supraphysiologic numbers of islets have been required to achieve long-term 
euglycaemia. Recently, a number of attempts have been made ta increase the 
efficiency of islet procurement and thus increase the number of people who can 
benefit from islet transplantation therapy [125, 203, 268-270]. These attempts are 
based on expanding the number or viability of isolated islets, which only constitute 
1-3% of the total pancreatic tissue [125, 203, 268]. If the unused and unwanted 
pancreatic acinar tissue, could be transformed into islet tissue there would be an 
immediate increase in ~-cell mass available for transplantation. Only a sm ail 
percentage would need to be transformed in order to greatly expand the 
transplantable ~-cell mass due to the large proportion of acinar tissue in the 
pancreas. We report here the development of an in vitro model of human acinar-
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to-duct-to-islet transformation. We demonstrate that the newly formed duct-like 
tissue exhibits islet neogenic potential and that ~-cell mass expansion can be 
inducted bya combination of gastrin, HGF and INGAp104.118. This novel model is 
not only highly relevant with respect to developing new sources of islet tissue, but 
it may also provide insight into the role of acinoductal metaplasia in the initiation of 
other pancreatic diseases. 
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4.2 MATERIALS AND METHODS 
4.2. 1 ln Vitro Acinar-to-fJ-cell Differentiation 
Pancreases fram seven cadaveric humans donors (cause of death was 
cerebral ischemia with no reported pancreatic disease) were dissected fram 
surraunding tissues and cannulated to permit intraductal infusion with Liberase HI 
(1.4 mg/ml) (Boehringer Mannheim, Indianapolis, IN, USA) according to 
established protocols [125]. Purification was achieved using a continuous density 
ficoll gradient (1.077-1.100 g/ml Biochram KG, Germany) and a COBE 2991 cell 
processor (COBE BCT, Denver, CO., USA). Tissue from the highest densities 
were washed and stained with diphenylthiocarbazone (dithizone, Sigma-Aldrich) 
to confirm lack of insu lin positive cells. 
Freshly isolated acinar clusters were embedded in type-1 rat tail collagen 
and cultured in DM consisting of DMEM/F12 (GIBCO, Burlington, ON, Canada) 
supplemented with 10% FBS (Montreal Biotech Inc., Montreal, QC, Canada), 
dexamethasone (1 f..I.M, Sigma-Aldrich, Canada, Oakville, Canada), EGF (10 
ng/ml, Sigma-Aldrich), 24 mU/mi insulin (Eli Lilly, Indianapolis, IN, USA) and 
cholera toxin (100 ng/ml, Sigma-Aldrich) (differentiation media, DM+CT). Cells 
were cultured in 95% air, 5% CO2 and 37°C, and the medium was changed on 
alternate days. Following 8 days of culture, when the acinar tissue had 
differentiated into duct-like epithelial structures, differentiation media without 
cholera toxin (DM) was administered ta the cells alone or supplemented with 
gastrin (50 nM, Sigma-Aldrich) and hepatocyte growth factor (10 ng/ml, Sigma-
Aldrich) (GH), INGAp104-118 (167 nM) (1) or GH and INGAp104-118 (GHI) for 6 days, 
Page 142 
with the medium changed every 2 days. After six days of treatment, cells were 
incubated with dithizone and insu lin positive islet-like structures were quantified, 
or tissue was removed from collagen using type XI collage nase (0.25 mg/ml, 
Sigma-Aldrich) and processed for immunohistochemistry. 
4.2.2 Microscopy and Morphometric Analysis 
Incidence of islet neogenesis was determined to be the total number of free 
standing dithizone positive structures (neo-islets) plus the total number of acinar-
derived duct-like structures (DLS) that had dithizone positive structures budding 
from them divided by the total number of structures counted. Following collagen 
digestion, samples were collected and embedded in paraffin wax. 
Pancreatic sections, 4 to 5 f.tm thick, were de-waxed in xylene and 
endogenous peroxidase activity was blocked using a 3% solution of hydrogen 
peroxide and methanol (for sections to be stained with 3,3'-diaminobenzidine 
tetrahydrochloride (DAS, Sigma-Aldrich)). Sections were then washed in PSS 
and incubated with blocking buffer (Histostain Plus Kit, Zymed Laboratories, San 
Francisco, USA) for 15 minutes at room temperature. Slides were stained with 
one or more primary antibodies, including insu lin (1 :750; Dako Diagnostics 
Canada, Mississauga, Canada); a cocktail of glucagon, somatostatin and 
pancreatic polypeptide (1 :750; Dako), C-peptide (1 :50; Siogenex, San Ramon, 
CA, USA), CK19 (1 :100; Dako), amylase (1 :100; Sigma-Aldrich), or PDX-1 (1 :750; 
a gift from C. Wright, Vanderbilt University). Siides stained for CK19 and PDX-1 
were incubated with 0.1 M citrate buffer for 9 minutes at 90°C for antigen retrieval 
before primary antibody application. Siides were incubated with primary 
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antibodies overnight at 4°C before being washed in PBS and incubated with the 
secondary antibodies for 20 minutes (Histostain Plus Kit, Zymed) at room 
temperature. Following washing in PBS, sections were incubated with 
horseradish peroxidase (Histostain Plus Kit, Zymed) for 20 minutes, and 
developed using DAB (Sigma-Aldrich). Double stained sections were then 
incubated with a second set of primary antibodies overnight at 4°C and the above 
process repeated. Alkaline phosphatase conjugate (Histostain Plus Kit, Zymed) 
was substituted for horseradish peroxidase and sections were developed with 
New Fuchsin (Dako). Ali light immunohistochemical si ides were counterstained 
with Harris' haematoxylin (Sigma-Aldrich) and cover slipped using Permount 
(Fisher Scientific, Ottawa, Canada). 
4.2.3 Statistical Analyses 
Comparison between groups was done using student Hest or an ANOVA 
with post hoc comparison where appropriate. Data are presented as mean ± 
standard error of the measurement. Significance was accepted at the 5% level. 
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4.3 RESULTS 
4.3. 1 ln Vitro Stimulation of Acinoductal Metaplasia 
Following isolation and embedding into collagen, the human pancreatic 
acinar tissue begins to lose its native structure and form cystic configurations 
(Figure 4.1 A). Greater than 95% of acinar clusters transformed into duct-like 
structures (OLS) that were devoid of amylase immunoreactivity and expressed the 
ductal epithelial marker CK19 (Figure 4.1 B). The acinar-to-OLS transformation, 
characterized by a loss of the central cells resulting in a hollowing of the acinar 
structure, appeared to initiate at one or multiple foci and then spread throughout 
the entire structure with duration in culture. By 8 days of culture this acinar-to-
duct transformation was complete. Acinar clusters between 50 to 250 f.tm2 almost 
always formed a single OLS whereas acinar clusters larger than 250 f.tm2 tended 
to form multiple OLS (Figure 4.1 Cl. Acini smaller th an 50 f.tm2 were more likely 
not to transform into OLS by the end of the 8 day culture period. 
4.3.2 Stimulation of Acinar-Derived DLS Transformation to Endocrine Phenotype 
Following 8 days of culture, the differentiation medium was replaced with 
medium that was devoid of cholera toxin and supplemented with various growth 
factor combinations. Following six days of culture with INGAp104-118 there was no 
morphological change in the acinar-derived OLS, and although there was a 
moderate increase in dithizone positivity there was no statistically significant 
difference (average number of structures/flask, p=0.11). When samples were 
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retrieved and processed for immunohistochemical analysis, a 18-fold increase in 
POX-1 immunoreactivity was observed versus controls (Figure 4.2). 
When acinar derived cystic structures were treated with a combination of 
gastrin, HGF and INGAp104-118 dithizone positive structures began to bud from the 
acinar-derived OLS (Figure 4.3). There was a significant increase in the 
percentage of dithizone positive structures budding from the acinar-derived OLS 
as weil as full neo-islet formation versus controls (p=O.037; Figure 4.4). Budding 
of dithizone positive structures occurred in 1.3±O.6, 1.4±O.2, 2.2±O.9 and 
5.1±O.2% of acinar-derived OLS in control, GH, l, and GHI-treated flasks, 
respectively. The percentage of neo-islet formation versus total structures was 
O.4±O.1, O.9±O.2, O.4±O.1 and 5.8±3.0% for control, GH, 1 and GHI-treated acinar-
derived OLS, respectively. 
ln order to rule out the possibility of the new islet-like-structures being 
dithizone positive due to the sequestering of the insu lin in the medium, 
immunohistochemical analyses for C-peptide and other islet hormones were 
performed. Immunohistochemical analyses of the growth factor (GHI) 
supplemented acinar-derived OLS indicated that these budding structures and 
neo-islets were immunopositive for C-peptide (Figures 4.5A and B), and in 
addition, were producing other endocrine hormones similar to a normal mature 
human islet (Figure 4.5C). 
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Figure 4.1: Transformation of adult human pancreatic acinar clusters into duct-
like structures (OLS). (A) Inverted micrographs of the differentiation of human 
acinar tissue into OLS following 8 days of culture. (B) Immunohistochemical 
staining for amylase (red) and the duct epithelial cell marker cytokeratin-19 
(brown) du ring this transformation process. (C) Photomicrograph of a large acinar 
cluster that differentiated into multiple OLS. (bar = 30 ~m) 
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Figure 4.2: POX-1 immunoreactivity of acinar-derived duct-like structure (OLS) 
treated with INGAp104-118 (167 nM) for 6 days_ (A) Photomicrograph of POX-1 
stained acinar-derived OLS that was treated with INGAp104-118 for 6 days. (8) 
Quantification of POX-1 positivityof INGAp104-118-treated acinar-derived OLS trom 
3 separate donor preparations. (bar = 20 !-lm) 
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Figure 4.3: Oifferentiation of acinar-derived duct-Iike structure (OLS) into islet-like 
structures. (A) Photomicrograph of dithizone stained acinar-derived OLS after 8 
days of culture. (8) Photomicrograph of a dithizone stained (red) acinar-derived 
OLS following four-day treatment with gastrin + HGF + INGAp104-118. (C) 
Photomicrograph of dithizone stained islet-like structure derived from a culture of 
acinar-derived OLS treated with gastrin + HGF + INGAp104-118 for 6 days. (bar = 
50 ~m) 
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Figure 4.4: Quantification of percentage of dithizone positive structures budding 
from acinar-derived DLS as weil as full islet-Iike structure formation in cultures of 
acinar-derived DLS treated with control media, gastrin + HGF, INGAp104-118, or 
gastrin + HGF + INGAp104-118 (n=4 separate organ preparations). * p<O.05 vs. ail 
other groups. 
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Figure 4.5: Immunohistochemical analysis of gastrin + HGF + INGApl04-118_ 
treated acinar-derived duct-like structure (OLS) cultures. (A) Photomicrograph of 
aC-peptide stained OLS that was treated with gastrin + HGF + INGApl04-118 (GHI) 
for 6 days. (8) Photomicrograph of C-peptide staining of an islet-like structure 
from a culture treated with GHI for 6 days. (C) Photomicrograph of a cocktail 
stained (anti-glucagon + anti-somatostatin + anti-pancreatic polypeptide) islet-like 
structure from a culture of GHI-treated acinar-derived OLS. (bar = 10 !-lm) 
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4.4 DISCUSSION 
Islet transplantation therapy has the potential to restore euglycaemia in 
individuals with type 1 diabetes, however due to the pau city of donor organs this 
therapeutic approach currently has a very limited impact. This situation could be 
reversed if an alternative source of islet tissue was identified and developed. In 
this study we provide evidence that adult human islet tissue can be expanded 
through the induction of acinar-to-islet transdifferentiation through a duct 
epithelial-like intermediate. Specifically, a combination of gastrin, HGF and the 
Reg family member INGAp104-118 produces a 6-fold increase in total dithizone 
positivity (10.9±2.9 vs. 1.7±0.4%) and a dramatic ....,15-fold increase in neo-islets 
compared to untreated control tissue cultures. 
Acinar-to-duct-like structure (OLS) interconversion and subsequent OLS-to-
islet-like structure transformation has been previously observed in multiple models 
of pancreatic regeneration [86, 89, 136, 137, 160, 170]. Wang et al. initially 
indicated that there was a corresponding increase in gastrin and TGFa expression 
following induction of OLS formation in adult Wistar rats that had been pancreatic 
duct-ligated [163]. Rooman et al. furthered this work with the critical observation 
that gastrin treatment of these duct-ligated rats led to enhanced duct-to-islet 
neogenesis from tubular complexes [137]. This duct-to-islet neogenesis was also 
associated with an upregulation of POX-1 in the ductal tissue, similar to that 
observed in our study. Moreover, we have previously shown that adult human 
islets also possess the morphogenetic plasticity to transform into OLS and then 
redifferentiate back into islet-like structures following administration of INGAp104-118 
[80, 125, 148]. 
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The transformation of adult human acini into DLS is most likely to occur 
through the extensive remodelling of the extracellular matrix. The pancreas 
digestion and tissue isolation procedure induces profound changes in the cell-cell 
and cell-extracellular matrix interactions, which are responsible for the regulation 
of cell phenotype [120-124]. The re-establishment of cell-matrix interactions using 
a non-native collagen matrix, together with cholera toxin-induced stimulation of 
cAMP, are most likely key factors in this phenotypic transformation [148, 271]. 
Furthermore, poor diffusion of nutrients and oxygen to the central regions of these 
acinar clusters probably further enhances the central 1055 of cells contributing to 
an enhanced formation of the cystic duct-like structures. 
Acinar-to-duct metaplasia is also characteristically seen in association with 
both chronic pancreatitis and pancreatic cancer [20, 128]. An in vitro human 
tissue model that enables the mechanistic study of acinoductal metaplasia, such 
as the model we describe here, may contribute to a better understanding of the 
process and origins of pancreatic adenocarcinoma [19, 20]. 
This model has also allowed us to determine the potential of human acinar 
tissue to generate new endocrine tissue. Following the addition of INGAp104-118 to 
the acinar-derived OLS there was a dramatic increase in POX-1 expression 
(Figure 4.2). However, the administration of the hamster Reg3 peptide INGAp104-
118 alone was not sufficient to produce a significant increase in insulin-producing 
cells, in contrast to results observed in islet-derived OLS cultures [125]. However, 
when INGAp104-118 was combined with gastrin and HGF there was a dramatic 
increase in insu lin positive tissue budding from these acinar-derived DLS leading 
to full islet formation. These in vitro results suggest that gastrin and EGF alone, 
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do not stimulate islet neogenesis from human acinar tissue. This is probably the 
case in vivo as weil, as ~-cell mass expansion only occurs when these factors are 
administrated in the setting of enhanced local expression of other growth factors 
[137,160,171,201,203]. 
Currently, islet transplantation therapy is hindered due to a lack of available 
tissue. Elucidation of a successful means of expanding islet-like tissue will enable 
a greater number of diabetic individuals to benefit from islet transplantation 
therapy. The exocrine tissue used in this study is routinely discarded following 
islet isolation procedures and as such, development of an acinar-to-islet 
differentiation model could drastically increase the amount of available endocrine 
tissue with no initial investment of critical pancreatic tissue. Furthermore, as 
exocrine tissue constitutes the majority of the organ there is ample tissue to 
dramatically increase the transplantable cell mass. Further studies will be 
required to determine if these acinar-derived islet-like structures will restore 
normoglycaemia in diabetic individuals to the same extent as primary islets. 
ln summary, the model of adult human acinar transdifferentiation described 
here is an important step in diabetes research that could lead to a new source of 
endocrine pancreatic tissue for transplantation. Furthermore, elucidation of the 
mechanisms involved could provide novel insights into the process of pancreatic 
carcinogenesis. 
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BRIDGING STATEMENT BETWEEN MANUSCRIPTS 
Chapters 2 through 4 have indicated that INGAp104-118 therapy can lead to 
PDX-1 upregulation, islet neogenesis and resultant ~-cell mass expansion, which 
remains under homeostatic regulation preventing unbridled ~-cell proliferation. 
Chapter 4 has indicated the potential of INGAp104-118 therapy to increase ~-cell 
mass in humans, through acinar-to-islet transdifferentiation. These results lead to 
the re-evaluation of the current therapies for diabetes mellitus as weil as the 
determination of effective future strategies for a safe and efficacious treatment of 
this disease. Chapter 5 looks at the current understanding of type 1 diabetes, the 
shortcomings of existing therapies for this disease, as weil as future therapies 
leading to the amelioration of this disease. 
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Current State Of, And Future Avenues For, 
The Treatment Of Type 1 Diabetes 
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5.0 ABSTRACT 
Current therapies for type 1 diabetes, including fastidious blood glucose 
monitoring and multiple daily insulin injections, are not sufficient to prevent 
complications of the disease. Though pancreas and possibly islet transplantation 
can prevent the progression of complications, the scarcity of donor organs limits 
widespread application of these approaches. Understanding the mechanisms of 
~-cell mass expansion as weil as the means to exploit these pathways has 
enabled researchers to develop new strategies to expand and maintain islet cell 
mass. Potential new therapeutic avenues include ex vivo islet expansion and 
improved viability of islets prior to implantation, as weil as the en doge no us 
expansion of ~-cell mass within the diabetic patient. Islet neogenesis, through 
stem cell activation and/or transdifferentiation of mature fully differentiated cells, 
has been proposed as a means of ~-cell mass expansion. Finally, any successful 
new therapy for type 1 diabetes via ~-cell mass expansion will require prevention 
of ~-cell death and maintenance of long-term endocrine function. 
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5.1 INTRODUCTION 
Type 1 diabetes mellitus afflicts millions of individuals worldwide and its 
prevalence and incidence continue to rise annually. This disease results from 
autoimmune mediated destruction of the insulin-producing J3-cells of the islets of 
Langerhans [8]. Despite the widespread use of meticulous blood glucose 
monitoring and new insulin formulations, most individuals with diabetes will still 
develop the devastating secondary complications of the disease. Clinical studies 
suggest that strict blood glucose control by intensified insulin treatment may 
attenuate or delay, but not prevent the eventual development of complications [62, 
256]. As such, exogenous insulin administration cannot match the glucose 
homeostasis provided by endogenous islets. 
Near perfect control of blood glucose levels can be restored by pancreas or 
islet transplantation, without the risk of serious hypoglycaemic episodes that are 
associated with intensive insu lin therapy [62]. Pancreas transplantation, however, 
is far more successful in maintaining long-term reversai of hyperglycaemia than 
islet transplantation [71, 272], which is still an emerging technology. Regardless, 
both approaches are of limited use due to the shortage of available organs and 
the need for chronic immunosuppression, relegating transplantation to a last 
resort therapy for individu ais with diabetes. Islet transplantation is further limited 
by poor isolation efficiency and the unresolved matter of islet death post-isolation 
[273]. Therefore, alternative strategies will need to be explored in order to 
develop a widely applicable therapy for the restoration of functional islet mass. 
A more innovative approach to islet replacement would be to harness the 
regenerative capacity of the pancreas. For example, islet regeneration could be 
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induced ex vivo using donor tissue as a means to expand the number of islets 
available for transplantation. Alternatively, in vivo induction of pancreatic 
regeneration leading to endogenous l3-cell mass expansion would also eliminate 
the necessity for donor tissue and thereby enable the widespread application of a 
regeneration therapy to restore normoglycaemia. However, due to the 
autoimmune nature of type 1 diabetes, as weil as the immune rejection associated 
with allogenic islet transplantation, such therapies would have to be coupled with 
an immunosuppressive regimen that would protect new islets. 
5.2 PATHOGENESIS 
Type 1 diabetes occurs due to autoimmune destruction of the pancreatic 13-
cells leading to an insufficient functional l3-cell mass. Evidence for the immune 
basis of the disease can be observed in the elevated levels of circulating auto-
antibodies to islet cell cytoplasm (ICA), insulin (IAA) and glutamic acid 
decarboxylase (GADA) [8J. 
5.3 Jl-CELL MASS DYNAMICS 
As with virtually every tissue in the body, l3-cell mass is dynamic [76, 79J. 
The magnitude of l3-cell mass is determined by the interplay between l3-cell mass 
expansion and reduction mechanisms. Expansion can occur through increases in 
l3-cell hypertrophy, hyperplasia and neogenesis (formation of new l3-cells from 
progenitor cells, Figure 5.1). Conversely, reduction can occur through l3-cell 
atrophy, death or loss of phenotypic stability. Accordingly, l3-cell mass expansion 
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could be achieved through the manipulation of any of these mechanisms, alone or 
in combination. 
5.3. 1 Mechanisms of f3-cell Mass Expansion 
The induction of endogenous j3-cell mass expansion could revolutionize 
diabetes therapy. Nonetheless, the development and implementation of this 
approach remains stalled due to uncertainty as to whether the principal 
mechanism of expansion is j3-cell hyperplasia or neogenesis. The importance of 
this distinction rests on the notion that j3-cell mass expansion on the basis of 
hyperplasia requires the persistence of j3-cells, a situation that may not exist in 
type 1 diabetes. 
While recent studies indicate a significant contribution of islet neogenesis 
to j3-cell mass expansion [139] another recent study by Dor et al. suggests 
otherwise [82]. In this study mice were engineered to express an inducible label 
behind an insulin promoter. Animais were 'pulsed' to label the insulin-producing 
cells at a set time and 'chased' thereafter to determine the contribution of these 
labelled cells to j3-cell mass. Based on the experimental outcome the authors 
concluded that replication of pre-existing j3-cells was the sole mechanism of j3-cell 
mass expansion. This observation ail but precludes the development of therapies 
based on the induction of endogenous j3-cell mass expansion. However, this 
study characterizes the dynamics of mouse j3-cell mass expansion, which differ 
from human j3-cell mass expansion dynamics [12, 236]. For example, Butler et al. 
have shown that in rodent models of insulin resistance and type 2 diabetes, 
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endogenous f3-cell mass expansion occurs primarily via proliferation [236]; 
whereas in patients with type 2 diabetes, f3-cell neogenesis is markedly 
upregulated and f3-cell replication is unchanged [12]. It is noteworthy that 
histologic evidence for ongoing islet neogenesis in non-diabetic individuals as weil 
as individuals with early-onset type 1 diabetes has also been reported [37]. These 
observations suggest that the restoration of f3-cell mass in type 1 diabetes may be 
achievable through the induction of endogenous f3-cell mass expansion via islet 
neogenesis. 
5.3.2 Mechanisms of f3-cell Neogenesis 
f3-cell neogenesis may occur through two pathways; stem/progenitor cell 
activation and/or transdifferentiation of adult pancreatic cells. Stem/progenitors 
cell-derived f3-cell mass expansion refers to the differentiation of a quiescent cell 
expressing primordial markers to yield insulin-producing f3-cells. The existence 
and identification of such a pancreatic stem cel! is still controversial [82, 118, 274]. 
By contrast, the ability to transdifferentiate from one mature cell phenotype to 
another cell phenotype reflects a degree of morphogenetic plasticity inherent to 
adult pancreatic tissue [125]. In this paradigm new f3-cells are derived from the 
transdifferentiation of a mature differentiated pancreatic cell (Le. duct or acinar) 
either directly, or through a process of dedifferentiation to a more primitive 
intermediate ce Il , followed by redifferentiation into an insulin-producing cel!. 
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5.4 THERAPY 
5.4. 1 Pharmacological Induction of fJ-cell Mass Expansion 
Current clinical research focuses on the stimulation of f3-cell mass 
expansion using pharmaceutical ligands. Unfortunately, human clinical data are 
not yet available, though compelling animal and in vitro human data does exist. 
5.4.1.1 Combined Gastrin and EGF 
Combination therapy of gastrin and epidermal growth factor (EGF) has 
been reported to exp and f3-cell mass in mice, potentially through increased f3-cell 
neogenesis [171]. Likewise, Suarez-Pinzon et al. have reported that the 
combination of gastrin and EGF leads to f3-cell expansion in long-term cultures of 
semi-purified human islets, possibly through islet neogenesis [203]. Moreover, it 
has also been reported that this therapy leads to increased insu lin and glucagon 
content in human islets transplanted into immunodeficient NOD mice [203]. Thus, 
these studies suggest that the combination of gastrin and EGF may have utility in 
expanding f3-cell mass both in vitro as weil as in vivo. 
5.4.1.2 GLP-1 
Glucagon-like peptide-1 (GLP-1), an incretin produced by enteroendocrine 
L-cells of the intestine, can reduce blood glucose levels through the inhibition of 
appetite, gastrointestinal motility and glucagon release, as weil as by the 
enhancement of glucose-stimulated insu lin release [47]. It has also been 
suggested that GLP-1 can induce f3-cell neogenesis from human progenitor cells 
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[274]. Unfortunately, there are few studies analysing the ability of GLP-1 to 
exp and ~-cell mass in the setting of type 1 diabetes. Nonetheless, the use of 
GLP-1 in vitro, and perhaps in vivo, may represent another means of manipulating 
~-cell mass. 
5.4.1.3 INGAp104-118 
Islet Neogenesis Associated Protein (INGAP) is a Reg family member 
identified in a hamster model of islet expansion. In vivo administration of a 
synthetically produced portion of INGAP (INGAp104-118) leads to the dose-
dependent expansion of ~-cell mass in normoglycaemic rodents and dogs, as weil 
as a reversai of hyperglycaemia in a mouse model of type 1 diabetes [139). More 
recently, INGAp104-118 has also been used to induce the in vitro differentiation of 
human islet-derived duct-like structures (OLS) back into glucose-responsive islets 
[125]. Unlike islets, these OLS are highly proliferative, and therefore represent a 
population of expandable putative progenitors that could be used to increase ~­
cel! mass for the purposes of islet replacement by transplantation. Similarly, 
acinar-derived OLS, when treated with a combination of gastrin, hepatocyte 
growth factor (HGF) and INGAp104-118, can also be induced to differentiate into 
islet-like structures. These findings suggest that adult human pancreatic acini 
also harbour the potential to expand ~-cell mass. 
Pharmacotherapies based on pancreatic tissue plasticity hold great 
promise as a means of increasing ~-cell mass in patients with diabetes. This is 
especially true for acinar-based expansion, given that acinar tissue constitutes 
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approximately 80% of pancreatic tissue and is discarded during routine islet 
isolation. 
5.4.2 Protection of Expanded fJ-cell Mass From Ongoing Autoimmunity 
While restoration of ~-cell mass is an obvious requirement for successful 
reversai of hyperglycaemia, maintenance of the new ~-cell mass is equally 
important. A neog~nesis-based therapy for type 1 diabetes will almost certainly 
require concomitant immunosuppressive therapy to prevent immune-mediated 
destruction of newly generated ~-cells (unless neogenic ~-cells are less 
immunogenic than the original ~-cells). New pharmacological regimens are in the 
early clinical trial phase and are designed to prevent ~-cell destruction in new-
onset type 1 diabetics and in individuals with latent autoimmune diabetes of the 
adult (LADA). Immunomodulatory therapeutic regimens focused on GAD [275] 
and heat shock protein 60 (Diapep277) [255] both appear to have at least 
marginal efficacy in the inhibition of insulitis and in decreasing insulin 
requirements. The successful development of these novel immunosuppressive 
therapies will allow for the protection of exogenously or endogenously expanded 
~-cell mass from the prevailing anti-~-cell leukocyte population. 
5.4.3 Inhibition of Non-Immune Mediated fJ-cell Death and Maintenance of Islet 
Phenotype 
It has been demonstrated that the standard method of islet isolation leads 
to the induction of islet apoptosis (Figure 5.2) [273]. During isolation, islets 
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experience growth factor withdrawal, loss of matrix support, osmotic stress, 
hypoxia and mechanical stress. As a result, pro-apoptotic signalling pathways are 
activated resulting in the activation of the intrinsic (mitochondrial) apoptotic 
pathway [276, 277J. Specific inhibition of early apoptotic signalling events can 
block the commitment to cell death by preventing activation of the intrinsic 
pathway, culminating in reduced islet cell apoptosis [276]. This approach could 
therefore represent a means of increasing islet isolation efficiency and enhancing 
islet viability. 
ln keeping with the notion that islet apoptosis may be implicated in loss of 
graft function, Verchere et al. have recently demonstrated that transplanted islets 
produce islet amyloid polypeptide (IAPP) at significant levels and that treatment of 
isolated islets with a hexapeptide inhibitor of amyloid plaque formation leads to a 
significant reduction in the number of amyloid plaques and apoptotic ~-cells, 
representing another means of increasing isolation efficiency (personal 
communication, CS Verchere). 
Loss of j3-cell mass may also occur through the loss of islet phenotype. 
Isolated islets have the capacity to dedifferentiate back to a duct-like state under 
certain environmental conditions [125J. Treatment of isolated islets with 
transforming growth factor-~ (TGF-j3) prevents islet-to-duct dedifferentiation and 
preserves islet morphology (unpublished observation). Thus, this would represent 
another approach to maintaining the function of transplanted islets, thereby 
improving islet transplant efficacy. 
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Another factor affecting the outcome of islet transplantation is the 
engraftment site. Currently, isolated islets are infused via the portal vein to 
engraft in the liver. This necessarily exposes the islets to elevated concentrations 
of glucose, lipids and immunosuppressive drugs that are ail likely to be f3-cell 
toxic. Better graft sites (Figure 5.3), including those that support islet neogenesis 
and growth [278], will help to resolve these issues and contribute to making cell-
based therapy preferable to whole organ transplantation. 
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5.5 CONCLUSION 
Novel cell-based therapies for diabetes are on the horizon. An increased 
understanding of the factors contributing to ~-cell mass dynamics has enabled 
researchers to examine new approaches to induce ~-cell mass expansion and 
promote survival. At this stage of development, it appears that any definitive 
therapy for type 1 diabetes will need to simultaneously address several issues 
including the induction of new islet formation, promotion of cell survival and long-
term maintenance of function, and the prevention of recurrent autoimmunity. 
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Figure 5.1: Photomicrograph of an insulin stained pancreatic section from an 
INGAp104-118-treated mouse. A duct-associated islet and single extra-islet p-cells 
indicate ongoing duct-to-islet neogenesis. (bar = 50 f.tm) 
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Figure 5.2: Fluorescence photomicrograph of a freshly isolated human islet of 
Langerhans double-stained with fluorescein diacetate (green: live cells) and 
propidium iodide (red: dead cells) indicates the islet cellioss that occurs following 
routine isolation. (bar = 20 ~m) 
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Figure 5.3: Photomicrograph of hamster islets and duct-like structures that were 
co-transplanted into the submucosal space of the sm ail intestine. Tritiated 
thymidine incorporation (dark nuclei) by cells in islets and duct-like structures 
indicate that this site supports progenitor and islet cell proliferation, while the 
transdifferentiation of duct-like structures into insulin-producing cells (red: insulin) 
indicate support for progenitor differentiation. (bar = 50 !-lm) 
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CHAPTER 6 
Discussion of Results and Concluding Statement 
Page 182 
6.0 ABILITY OF INGAp104-118 TO STIMULATE ISLET NEOGENESIS 
The primary objective of this thesis was to determine the regenerative 
potential of INGAp104-118 in multiple species (Chapter 2)_ As diabetes results from 
an inadequate insulin-producing ~-cell mass to meet the body's requirements, the 
formation of new islets from endogenous progenitors would be a significant 
advancement in diabetes therapy. Before INGAp104-118 could be used as a 
diabetes therapy its efficacy beyond the original hamster setting needed to be 
determined. 
INGAp104-118 administration to normoglycaemic hamsters led to a greater 
than 30% increase in total ~-cell mass in comparison to age-matched controls 
(Figure 2.3A). As total ~-cell mass can increase through various pathways 
(Chapter 1), it was important to perform astringent analysis of ~-cell mass 
dynamics in order to determine the exact mechanism(s) of ~-cell mass expansion 
in this setting. Wh en a thorough analysis of ~-cell mass dynamics was pertormed, 
it was found that INGAp104-118 therapy stimulated islet neogenesis via extra-islet ~­
cells associated with both acini and ducts (Figure 2.4). These findings support 
previous reports of an initial reduction in average islet size, which is a surrogate 
marker of islet neogenesis [85]. 
This study then sought to determine whether INGAp104-118 had the potential 
to stimulate ~-cell mass expansion in mice. INGAp104-118 was administered to 
normoglycaemic mice for a period of 31 days, after which point, the ~-cell mass 
was observed to increase by more than 120% (Figure 2.5). In addition to this 
dose-dependent expansion of endogenous ~-cell mass in normal mice, INGAp104-
Page 183 
118 therapy was observed to exp and the ~-ce" mass in a murine model of type 1 
diabetes. This expansion appeared to occur similarly to the ~-cell mass 
expansion observed during embryology, showing a dramatic increase in PDX-1 
expression (Figure 2.8). These results suggest that INGAp104-118 can lead to 
endogenous ~-ce" mass expansion in various rodent settings and that this 
expansion is sufficient to reverse chronic hyperglycaemia. 
It is interesting to note that in these diabetic mice, an autoimmune-
mediated destruction of the pancreatic ~-cells destroyed the original ~-ce"s but 
Iymphocytic infiltration (insulitis) was not observed to encroach upon the newly 
formed islets. There are three possible explanations for this occurrence. Firstly, 
the newly formed ~-ce"s may not express the same antigenic profile as the 
original ~-cells, and thus they are spared from insulitis. Secondly, INGAp104-118 
may have immunomodulatory properties that inhibit streptozotocin-induced 
insulitis. Thirdly, the induced insulitis may not appropriately model the 
autoimmunity observed in type 1 diabetes, and following restoration of ~-cell mass 
via INGAp104-118 therapy the autoimmune leukocyte population is less active. 
Consequently, future studies are required to determine the exact mechanism(s) of 
neo-islet protection in this model of type-1 diabetes. 
When euglycaemic beagle dogs were administered INGAp104-118, there was 
a trend to increase ~-cell mass, suggesting that INGAp104-118 has the potential to 
expand ~-cell mass in higher mammals (Figure 2.10). This point is further 
supported by the observation of profound islet neogenesis occurring in 
cynomolgus monkeys that were injected with INGAp104-118 for 90 days (Figure 
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r-.. 2.12). Not only was INGAp104-118 therapy sufficient to stimulate p-cell mass 
expansions in various animais, but it was also able to reverse overt 
hyperglycaemia in a rodent model of type 1 diabetes (Figure 2.6). 
6.1 MECHANISMS OF fl-CELL MASS EXPANSION 
As indicated in Chapter 1, p-cell mass expansion can occur through three 
cellular pathways including, growth of pre-existing p-cells, differentiation of 
endogenous stem cells and transdifferentiation of mature cell phenotypes. The 
studies included in this thesis suggest that INGAp104-118 leads to p-cell mass 
expansion through both direct and indirect transdifferentiation of mature cell 
phenotypes (Chapters 2-4) as weil as through the moderate growth of pre-existing 
p-cells (Chapter 3). Conclusive evidence that INGAp104-118 stimulates activation of 
endogenous stem cells has not been found. However, it is possible that 
endogenous stem cells exist and reside amongst mature duct and acinar tissue 
and are only activated when appropriate changes occur in the extracellular 
environment that promote their differentiation toward an endocrine phenotype [20, 
125,279]. 
Changes in the extracellular matrix have been implicated in initiating 
cellular differentiation [81, 125, 147-149]. It is possible that INGAp104-118 binding to 
appropriate sites on progenitor cells initiates signalling cascades and changes in 
the extracellular matrix, which in turn enables endocrine differentiation [190}. 
Changes in the extracellular matrix, along with elevated intracellular cAMP, are 
involved in the phenotypic conversion of isolated islets and acini into duct-Iike 
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structures [148, 149, 280, 281J. The changes in extracellular matrix, along with 
the addition of INGAp104-118, gastrin and HGF lead to endocrine transformation, 
either through transdifferentiation of dedifferentiated duct-like cells, or through the 
activation of previously quiescent stem cells adjacent to these structures. 
Unfortunately, using current cellular labelling techniques it may be difficult to 
clearly delineate from precisely which tissue types these new endocrine cells are 
arising in human cultures. 
Recently, Dor et al. used a novel experimental technique for tracing the 
lineage of progenitor ceUs within the murine pancreas [82J. The authors used a 
Cre/lox system of inducible progenitor ceU labelling to quantify the mechanism(s) 
of ~-cell growth and regeneration in adult mice. Briefly, a transgenic mouse was 
created in which an inducible label would be expressed in insulin-producing cells 
and ail of the labelled cells' progeny. Following a pulse of the inducer, animais 
were sacrificed at various time points and the percentage of labelled islets and ~­
ceUs were determined. The authors found no change in the percentage of islets 
and ~-ceUs labelled prior to the chase period in comparison to following, in both 
normal mice as weil as in 60% partial pancreatectomized mice. Dor et al. 
interpreted these results to mean that ~-cell expansion only occurs through 
duplication of pre-existing ~-cells in adults. However, Minami et al. have shown 
that pancreatic exocrine tissue transforms into insulin-producing tissue using a 
similar Cre/lox technique. Furthermore, other researchers have indicated possible 
technical insufficiencies involved in Dor et al.'s study, which may account for their 
observed results and thus, their controversial conclusion [115, 117,279,282). 
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As stated in Chapter 1, islet neogenesis in adults appears to recapitulate 
the J3-cell mass expansion observed during pancreatic ontogeny. Diabetic mice 
treated with INGAp104.118 showed an increase in duct-cell PDX-1 positivity, 
consistent with that which is observed du ring pancreatic organogenesis (Figure 
2.8) [91, 97, 98, 102]. This upregulation of PDX-1 in potential ductal progenitors is 
also seen in duct-like structures derived from human acini treated with INGAp104. 
118 (Chapter 4). In the context of these in vitro structures, however, INGAp104.118 
administration alone was insufficient to stimulate a statistically significant 
expansion of insulin-producing cells. These results suggest that even though 
PDX-1 is a critical component of mature J3-cell function, it may not be an accu rate 
marker of a fully functional and mature endocrine phenotype [159]. This finding is 
in keeping with the fact that virtually ail cells express PDX-1 during pancreatic 
ontogeny, though only a small minority (-3%) ever become endocrine cells. 
Therefore, other, more specific markers of islet neogenesis should be used in 
addition to PDX-1, such as NGN-3 and/or islet-1, to perform a more robust 
determination of endocrine differentiation potential. 
A critically important finding of this thesis is that administration of INGAp104. 
118 leads to islet neogenesis through a multitude of pathways. We have observed 
the following processes in settings of J3-cell mass expansion: a dramatic increase 
in PDX-1 upregulation and duct-to-islet differentiation in diabetic mice (Figure 2.8), 
duct-to-islet and acinar-to-J3-cell differentiation in normoglycaemic hamsters 
(Figure 2.4), duct-to-islet differentiation in normoglycaemic mice (Figure 3.4), and 
indirect acinar-to-duct-to-islet differentiation in monkeys (Figure 2.11). 
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Furthermore, INGAp104-118 may also induce ~-cell mass expansion through ~-cell 
hypertrophy (Figure 3.6A) [179J. Moreover, a mild reduction in ~-cell apoptosis 
was observed at 31 days of INGAp104-118 therapy, and although this result is not 
significant (p=O.33), it suggests that INGAp104-118 may exp and ~-cell mass through 
this mechanism as weil. INGAp104-118 has previously been shown to promote anti-
apoptotic activity in human islet-derived duct-like cells, and a full-Iength 
recombinant INGAP was found to prevent peroxide-mediated cell death in isolated 
human islets (personal communication, Lawrence Rosenberg) [125]. INGAp104-118 
therefore appears to enhance ~-cell mass through multiple pathways, and thus 
could possibly be used in diabetic individuals to promote ~-cell mass expansion 
and subsequent glucohomeostasis. 
The results described herein strongly suggest the occurrence of islet 
neogenesis in the various described animal settings. Even so, one must be 
conscious of the potential shortcomings of the techniques used in this thesis work. 
Currently there is much debate as to whether or not islet neogenesis plays a role 
in 13 -cell mass expansion in adult animais [25, 82, 118, 119J. 
Immunohistochemical techniques were used to quantify the occurrence of islet 
neogenesis in this thesis. Unfortunately, due to the nature of 
immunohistochemistry only static measurements of each tissue sample can be 
made. Islet neogenesis and ~-cell mass expansion are dynamic processes and 
consequently, immunohistochemical analyses do not provide an infallible me ans 
of identification and quantification of this process. As described above, one way 
to circumvent this limitation is to perform genetic manipulations leading to the 
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labelling of a certain tissue genotype [82, 115}. These cells can then be followed 
with time in order to determine what cellular factors they come to express. 
Unfortunately, these manipulations can intraduce biases into the animal models 
used and have a number of idiosyncrasies and imperfections associated with 
them leading to difficulties in interpreting the resulting data [115, 117, 279, 282}. 
Hopefully in the near future this technique will become perfected enabling a 
stringent cellular tracing pratocol. 
An alternative interpretation of the results of this thesis could be derived 
based on the knowledge that Reg prateins are duct cell mitogens [158, 184, 190]. 
The increased duct-associated ~-cell mass in these animal models may have 
arisen not fram duct-to-~-cell neogenesis, but fram ductal growth into pre-existing 
islets. The increase in extra-islet duct-associated clusters would suggest against 
this interpretation, though one cannot rule this out as a possible mechanism for 
the increased duct-associated ~-cell mass. Furthermore, in the setting of human 
acinar-to-islet transformation, it is possible that endocrine tissue was present in 
the initial acinar tissue culture, even though it was not visible using dithizone 
staining. This endocrine tissue could have remained quiescent thraugh the 
transformation pracess to duct-like structures. Following the removal of cholera 
toxin and addition grawth factors to the culture medium, these endocrine cells may 
have then proliferated to give rise to the islet-like structures. An apprapriate 
cellular lineage experiment in which acinar tissue is labelled and then traced 
thraughout the transformation pracess would enable determination if these newly 
forming endocrine clusters were truly derived fram acinar cell differentiation. 
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Even with the potential limitations indicated above, it appears that 
INGAp104-118 do es contain the ability to stimulate endocrine cell expansion in many 
different species. As such, INGAp104-118 could potentially be used as a therapeutic 
measure to expand the insulin-producing p-cell mass in individuals with diabetes. 
6.2 POTENTIAL OF INGAp104-118 THERAPY TO RESTORE EUGL YCAEMIA IN 
HUMANS 
INGAp104-118 administration can expand the insulin-producing p-cell mass in 
a number of species and stimulate islet neogenesis in vivo in monkeys, as weil as 
in vitro in human tissue cultures. These results imply that INGAp104-118 
administration to humans would result in expanded p-cell mass and thus could 
potentially restore euglycaemia in diabetic individuals. 
Recently, phase 2 clinical trials were performed to test the efficacy of 
INGAp104-118 in human subjects with type 1 or type 2 diabetes [265J. Analysis of 
endogenous insulin release and long-term glycaemic homeostasis were 
performed in INGAp104-118 and placebo treatment groups. Endogenous insulin 
release was determined via measurements of arginine-stimulated C-peptide 
secretion [265J. Long-term glycaemic control was assessed by measuring the 
extent of non-specifie glycosylation of the haemaglobin A1c site, which normally 
ranges between 4 and 6% [283]. 
INGAp104-118 administration resulted in a statistically significant increase in 
arginine-stimulated C-peptide release (p=O.006) in type 1 patients as weil as a 
trend towards lowering of glycosylated haemaglobin A1C levels (6.8 vs. 7.1%; 
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p=0.10). In type 2 patients, there was no statistically significant difference in 
arginine-stimulated C-peptide release, but a significant decrease in glycosolated 
haemaglobin levels (HgA1c 7.0 vs. 7.6%; p=0.04). Unfortunately, INGAp104.118 was 
not weil tolerated by the type 1 population, and there was a large number of drop-
outs and a corresponding reduction in power of the study. Hopefully, advances in 
peptide stability, administration technique and general efficacy of this peptide will 
lead to a reduced peptide dosage and a corresponding decrease in associated 
si de effects. 
The results of this thesis, as weil as the results of the preliminary clinical 
trials, suggest that INGAp104.118 does indeed have the potential to expand the ~­
cel! mass and lead to greater control of diabetic hyperglycaemia. 
6.3 SAFETY OF PHARMACOLOGICAL INDUCTION OF ~-CELL MASS 
EXPANSION 
Exogenous stem cell therapy has been associated with the induction of 
numerous incidences of cancer, and as such, there is restricted optimism when 
considering this therapy as a potential treatment modality [20, 128, 284]. As 
indicated in Chapter 1, pancreatic adenocarcinoma is a devastating disease with a 
less th an 10% 1-year survival rate. Activation of endogenous progenitors within 
the pancreas via pharmacological therapy may also lead to an increased 
incidence of pancreatic adenocarcinoma or other cancers [20, 128]. Multiple~­
cell neogenic agents (including EGF, gastrin, Reg1 and Reg4) have been closely 
associated with gastrointestinal cancers [128, 176, 178, 205, 206]. Therefore, it is 
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of utmost importance to determine if exogenous administration of these factors 
would lead to increased incidence of pancreatic carcinogenesis. 
Although INGAp104-118 is a Reg3 protein, it has similar effects to Reg1 and 
Reg4, such as stimulating the proliferation of epithelial cells and potentially 
initiating acinoductal metaplasia [125, 158]. As indicated, acinoductal metaplastic 
transformation is observed in multiple examples of pancreatic regeneration as weil 
as in the progression of adenocarcinoma [20, 86, 89, 115, 128, 129, 135-138, 
170]. It is therefore important to clarify whether INGAp104-118 therapy holds the 
potential to induce acinoductal metaplasia and possible facilitation of pancreatic 
adenocarcinoma. Even though the metaplastic transformation of acinar tissue 
was only observed in monkeys administered an extremely high dose of INGAp104-
118 (400 mg/kgobw versus the maximum dose of ..... 8 mg/kgobw in the human trials) 
a thorough analysis of carcinogenic potential of any neogenic agent must be 
performed prior to broad spectrum introduction of such a therapy for the treatment 
of diabetes mellitus. Overexpression of a Reg protein immunoreactive to an anti-
INGAP antibody was found to be associated with reactive hypoglycaemia in an 
individual following pancreas transplantation, further justifying the need for 
research into INGAp104-118 pharmacodynamics [285]. 
Our research has taken initial steps towards elucidating whether INGAp104-
118 induces unbridled pancreatic cell growth (Chapter 3). Findings showed that 
even at extreme doses, there was no unregulated expansion of ~-cells in either 
mice or monkeys after 90 days of INGAp104-118 therapy. Homeostatic regulation of 
induced ~-cell mass expansion occurred through the reduction in proliferation of 
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mature ~-cells and the concomitant 4-fold increase in ~-cell apoptosis, indicating 
that the animais' regulatory mechanisms were working appropriately to keep their 
~-cell mass at required levels (Figure 3.6). 
6.4 PANCREATIC PLASTICITY: THE ACINAR-DUCT-ISLET AXIS 
The pancreas has been described as being two separate entities, the 
exocrine pancreas and the endocrine pancreas [51, 52]. This antiquated 
description is an inaccurate representation of how the pancreas functions in 
instance of disease and regeneration. The studies of this thesis, as weil as 
numerous other investigations have indicated that each cell type within the adult 
pancreas contains the ability to transform into the other pancreatic cell 
phenotypes [52, 125, 128, 135, 138, 139, 144]. Acini, ducts and islets can ail 
transform into primordial duct-like structures, which can th en transform into any of 
the three mature cell phenotypes. Furthermore, acinar, duct and endocrine cells 
can transform directly into ~-cells. The change in cell phenotype and gene 
expression of the three main cell phenotypes in the adult pancreas iIIustrates that 
the organ has multiple pathways that can lead to appropriate tissue expansion. A 
better understanding of the mechanism behind cellular plasticity will facilitate new 
strategies for the effective treatment of disease states. 
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6.5 FUTURE DIRECTIONS OF PHARMACOLOGICAL INDUCTION OF ~-CELL 
MASS EXPANSION 
The studies of this thesis sought to determine if pharmacological initiation 
of islet neogenesis could be an effective means for the stimulation of ~-cell mass 
expansion and reversai of diabetic hyperglycaemia. INGAp104-118 has been shown 
to stimulate islet neogenesis in a manner similar to the highly regulated process 
that occurs du ring pancreatic ontogeny. Significant advancements have been 
made toward developing an effective pharmacological agent for the successful 
stimulation of j3-cell mass expansion, which may form the basis of future therapies 
for the treatment of diabetes. It is likely that the most effective therapy for type 1 
diabetes will involve a multimodal approach, including neogenic agents (such as 
INGAp104-118), agents to moderate glycaemic profile (such as Amylin, or GLP-1), 
and selective anti-Ieukocyte therapies. Such a combination of therapies may 
finally lead to the restoration of euglycaemia in diabetic individuals and prevent 
the devastating complications associated with this disease. 
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6.7 CONCLUSIONS 
From the initial hypothesis and objectives of this thesis, to the experiments 
subsequently performed and the interpretation of their results, the following 
conclusions can be made: 
1. The mechanism of action of INGAp104·118 is indeed through stimulation of 
islet neogenesis, and not through replication of pre-existing ~-cells. This 
effect of INGAp104.118 treatment is not species specific, as it can stimulate 
islet neogenesis in a broad spectrum of mammals, including human. 
Furthermore, INGAp104·118 is effective at stimulating islet neogenesis and 
subsequent ~-cell mass expansion in a dose dependent manner. 
2. Similar to that observed during pancreatic organogenesis and new islet 
formation, INGAp104·118 stimulates duct-to-islet transdifferentiation associated 
with increased PDX-1 expression. As weil, INGAp104.118 can enhance f3-cell 
mass through both direct and indirect acinar-to-f3-cell transdifferentiation, 
suggesting multiple avenues of potential f3-cell mass augmentation. 
3. Induction of f3 -ce Il mass expansion, through continuai administration of 
INGAp104·118 occurs in a highly regulated manner in which the body's 
homeostatic mechanisms act to prevent unbridled cellular growth, ensuring 
the resultant f3-cell mass remains at the level required. 
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7.0 ORIGINAL CONTRIBUTIONS TO KNOWLEDGE 
"This requirement is mandatory for ail McGili University doctoral theses. Elements 
of the thesis that are considered to constitute original scholarship and an 
advancement of knowledge in the domains in which the research was conducted 
must be clearly indicated." 
1. In vivo, INGAp104.118 is effective at stimulating quantifiable islet neogenesis in 
mice, hamsters and monkeys. 
2. INGAp104.118 is effective at stimulating islet neogenesis and increasing j3-cell 
mass in a dose-dependent manner in mice. 
3. INGAp104·118 acts, via a POX-1 mediated neogenic pathway to enhance j3-cell 
mass. 
4. INGAp104.118, in combination with gastrin and HGF, can stimulate islet 
neogenesis and j3-cell mass expansion in cultures of human acinar tissue. 
5. Induced j3-cell mass expansion, via INGAp104-118 administration, remains under 
homeostatic regulation. Following continuai exposure to this neogenic agent 
there is decreased j3-cell replication and increased j3-cell apoptosis, 
maintaining the resultant j3-cell mass at appropriate levels. 
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